

*ARYA Atherosclerosis* has been licensed as a scientific & research journal by the Iranian commission for medical publications, ministry of health and medical education

Serial Issue: 53

Volume 12, Issue 3, May 2016

Print ISSN: 1735-3955

Online ISSN: 2251-6638

### Editorial

**Orthopedic problems: An underestimated hidden risk factor for development and progression of atherosclerosis; An inconspicuous joint link**  
Mohaddeseh Behjati ..... 115-117

### Original Article(s)

**Lipid peroxidation and antioxidant enzymes activity in controlled and uncontrolled Type 2 diabetic patients**  
Mahnaz Zarei, Zahra Farahnak, Mohammad Javad Hosseinzadeh-Attar, Mohammad Hassan Javanbakht, Payam Hosseinzadeh, Hoda Derakhshanian, Payam Farahbakhsh-Farsi, Mahmoud Djalali ... 118-123

**Comparison of health-related quality of life after percutaneous coronary intervention and coronary artery bypass surgery**  
Razieh Yazdani-Bakhsh, Mehdi Javanbakht, Masoumeh Sadeghi, Atefeh Mashayekhi, Hossein Ghaderi, Katayoun Rabiei .... 124-131

**Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cerebrovascular event in an Iranian cohort study: The Isfahan Cohort Study**  
Davoud Kazemi-Saleh, Pooya Koosha, Masoumeh Sadeghi, Nizal Sarrafzadegan, Reza Karbasi-Afshar, Mansoureh Boshtam, Shahram Oveis-Gharan ..... 132-137

**What is role of sex and age differences in marital conflict and stress of patients under Cardiac Rehabilitation Program?**  
Saeid Komasi, Mozghan Saeidi ..... 138-145

**Predicting metabolic syndrome using decision tree and support vector machine methods**  
Farzaneh Karimi-Alavijeh, Saeed Jalili, Masoumeh Sadeghi ...146-152

### Case Report(s)

**Reversible left bundle branch block should be mentioned in cardiac resynchronization therapy; A clinical case report**  
Ali Vasheghani-Farahani, Masih Tajdini, Seyed Abolfazl Mohsenizadeh, Seyed Mohammad Reza Hosseini ..... 153-155

### Letter to Editor(s)

**Normal range of bleeding time in west of Iran**  
Hassan Mansouritorghabeh ..... 156-157

### Indexed by:

- ✓ PubMed
- ✓ PubMed Central
- ✓ Scopus
- ✓ Islamic World Science Citation (ISC)
- ✓ WHO/EMRO/Index Medicus
- ✓ NLM Catalog
- ✓ Directory of Open Access Journals (DOAJ)
- ✓ Index Copernicus
- ✓ Academic Search Complete EBSCO Publishing databases
- ✓ Scientific Information Database
- ✓ Open J Gate
- ✓ Google Scholar
- ✓ Iranmedex
- ✓ Magiran



---

# **ARYA** *Atherosclerosis*

---

Official Journal of the Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences

## **CHAIRMAN**

**Nizal Sarrafzadegan, MD**  
Professor of Cardiology, Isfahan Cardiovascular  
Research Institute,  
Isfahan University of Medical Sciences, Isfahan, Iran

## **ASSOCIATE EDITOR**

**Hamidreza Roohafza, MD**  
Assistant Professor, Isfahan Cardiovascular Research  
Center, Isfahan Cardiovascular Research Institute,  
Isfahan University of Medical Sciences, Isfahan, Iran

## **SENIOR EDITOR**

**Masoud Pourmoghaddas, MD**  
Professor of Cardiology, Isfahan Cardiovascular Research  
Center, Isfahan Cardiovascular Research Institute,  
Isfahan University of Medical Sciences, Isfahan, Iran

## **Jamshid Najafian, MD**

Associate Professor,  
Isfahan Cardiovascular Research Institute,  
Isfahan University of Medical Sciences,  
Isfahan, Iran

## **EDITOR-IN-CHIEF**

**Masoumeh Sadeghi, MD**  
Professor of Cardiology, Cardiac Rehabilitation Research  
Center, Isfahan Cardiovascular Research Institute, Isfahan  
University of Medical Sciences, Isfahan, Iran

## **SECTION EDITORS**

**Mojgan Gharipour, MSc:** PhD Candidate, Molecular Epidemiology, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Allahyar Golabchi, MD:** Fellowship of Interventional Electrophysiology, Cardiac Electrophysiology Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran

**Alireza Khosravi, MD:** Associate Professor, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Noushin Mohammadifard, MSc:** PhD Candidate, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Hamidreza Roohafza, MD:** Assistant Professor, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Golnaz Vaseghi, Pharm D, PhD:** Assistant Professor, Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

## **MANAGING EDITOR**

**Mojgan Gharipour, MSc**  
PhD Candidate, Molecular Epidemiology, Isfahan  
Cardiovascular Research Institute, Isfahan University  
of Medical Sciences, Isfahan, Iran

## **STATISTICAL CONSULTANT**

**Awat Feizi, PhD**  
Associate Professor, Department of Biostatistics and  
Epidemiology School of Public Health,  
Isfahan University of Medical Sciences, Isfahan, Iran

## **REVIEWER SESSION MANAGER**

**Pouya Nezafati, MD**  
Head of Cardiac Surgery Research Committee, Department of Cardiac  
Surgery, Mashhad University of Medical Sciences, Mashhad, Iran

---

**Publisher:** Isfahan University of Medical Sciences,  
Email: publications@mui.ac.ir

**Copy Edit, Layout Edit, Design, Print and Online Support:** Farzanegan Radandish Publications  
<http://www.farapub.com>  
Email: f.radandish@gmail.com

---

**Circulation:** 500  
**Distribution:** International  
**Language:** English  
**Interval:** Bimonthly  
**Print ISSN:** 1735-3955, **Online ISSN:** 2251-6638

---

---

## EDITORIAL BOARD (Alphabetic order)

---

**Peyman Adibi, MD**

Associate Professor, Department of Gastroenterology, Isfahan University of Medical Sciences, Isfahan, Iran

**Alireza Ahmadi, MD**

Department of Preventive Pediatric Cardiology, Isfahan Cardiovascular Research Center, Isfahan, Iran

**Mousa Alavi, PhD**

Nursing and Midwifery Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

**Masoud Amini, MD**

Professor, Department of Endocrinology, Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

**Bahram Aminian, MD**

Professor, Department of Medicine and Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran

**Sedigheh Asgary, PhD**

Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan, Iran

**Leila Azadbakht, PhD**

Associate Professor, Department of Nutrition, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

**Majid Barekatin, MD**

Associate Professor, Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran

**Nooshin Bazargani, MD**

Board Member of Emirates Cardiac Society Board, Member of World Heart Federation Consultant Cardiologist, Dubai Hospital, Dubai

**Maryam Boshtam, MSc**

PhD Candidate, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

**A Chokalingam, MD**

Professor, School of Medicine, Simon Fraser University, Burnaby, BC

**Minoo Dianatkah**

MSc in Biostatistics, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Abolghasem Djazayeri, MD, PhD**

Professor, Department of Nutrition and Biochemistry, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran

**Ahmad Esmailzadeh, PhD**

Associate Professor, Department of Nutrition, Department of Nutrition, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

**Armen Gaspayan, MD, PhD**

Associate Professor, School of Medicine, Chief Editor of European Science Editing, UK

**Yousof Gheisari, MD, PhD**

Assistant Professor, Department of Biotechnology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Shaghayegh Haghjooy Javanmard, PhD**

Physiology Research Center, Isfahan University of medical sciences, Isfahan, Iran

**Hoda Javadikasgari, MD**

Department of Thoracic and Cardiovascular Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA

**Roya Kelishadi, MD**

Professor, Department of Pediatrics, Child Health Promotion Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

**Hossein Khosravi-Boroujeni, PhD**

Department of Public Health, School of Medicine AND Menzies Health Institute, Gold Coast Campus, Griffith University, Queensland, Australia

**Darwin R Labarthe, MD**

Associate Director for Cardiovascular Health Policy and Research, Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Washington, DC

**Bagher Larijani, MD**

Professor, Research Institute for Endocrine Sciences (R.I.E.S), Tehran University of Medical Sciences, Tehran, Iran

**Mohammad Lotfi, MD**

Professor, Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran

**Hossein Malekafzali, MD, PhD**

Professor, Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

**Mohammad Hossein Mandegar, MD**

Professor, Department of Cardiovascular Surgery, Tehran University of Medical Sciences, Tehran, Iran

**Arya Mani, MD**

Professor, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT

**Gholamreza Masoumi, MD**

Associate Professor, Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Saeed Mirsadraee, MD**

Consultant Cardiothoracic Radiologist, Department of Radiology, Royal Infirmary of Edinburgh AND Senior Lecturer in Clinical Radiology, University of Edinburgh, Edinburgh, United Kingdom

**Ahmad Movahedian, PhD**

Professor, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

**Mohammad Navab, MD, PhD**

Professor, Department of Medicine, David Geffen School of Medicine, The University of California, Los Angeles, CA

**Ebrahim Nematipour, MD**

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

**Mohammad Hassan Nezafati, MD**

Associate Professor, Cardiac Surgery Department of Cardiac Surgery, School of Medicine AND Imam Reza General Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

**Pouya Nezafati, MD**

Head of Cardiac Surgery Research Committee, Department of Cardiac Surgery, Mashhad University of Medical Sciences, Mashhad, Iran

**Sania Nishtar, MD**

Professor, Department of Cardiology, Founder and President, Heart file, Islamabad, Pakistan

**Firdon Noohi, MD**

Professor, Department of Cardiology, Shaheed Rajaei Cardiovascular Medical and Research Center, Tehran, Iran

**Katayoun Rabiei, MD**

PhD Candidate, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Mohammad Saadatnia, MD**

Associate Professor, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Javad Shahabi, MD**

Assistant Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Shahzad Shahidi, MD**

Associate Professor, Department of Nephrology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Vahid Shayannejad, MD**

Associate Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Mohammad Shenasa, MD**

Professor, Department of Cardiovascular Services, O'Connor Hospital, San Jose, CA

**Shahin Shirani, MD**

Associate Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Bahram Soleimani, PhD**

Associate Professor, Department of Epidemiology and Biostatistics, Najafabad Branch, Islamic Azad University, Isfahan, Iran

**Kusam Sudhakar Reddy, MD, DM**

Professor, Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India

**Mohammad Talaei, PhD**

Saw Swee Hock School of Public Health, National University of Singapore, Singapore AND Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**Ali Akbar Tavassoli, MD**

Associate Professor, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

**E Vartianian, PhD**

Professor, Department of Epidemiology, National Public Health Institute, Helsinki, Finland

---

### OFFICE ADMINISTRATOR

Leila Shahin

MSc in Language Teaching, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

---

**Address:** ARYA Journal Office, Isfahan Cardiovascular Research Institute, Seddigheh Tahereh Research Complex,

Khorram Ave. Isfahan, Iran

PO. Box: 81465-1148

Email: [arya@crc.mui.ac.ir](mailto:arya@crc.mui.ac.ir)

Tel: +98-311-3377883

Fax: +98-311-3373435

Web: [www.aryajournal.ir](http://www.aryajournal.ir)

# ARYA Atherosclerosis

## INSTRUCTIONS FOR AUTHORS

### MANUSCRIPTS

Manuscripts containing original material are accepted for consideration if neither the article nor any part of its essential substance, tables, or figures has been or will be published or submitted elsewhere before appearing in the *Journal*. This restriction does not apply to abstracts or press reports published in connection with scientific meetings. Copies of any closely related manuscripts must be submitted along with the manuscript that is to be considered by the *Journal*. Authors of all types of articles should follow the general instructions given below. Please see Types of Articles for specific word counts and instructions.

### SUBMISSION

- Only online submission is acceptable. Please submit online at: <http://www.aryajournal.ir>
- Manuscripts should be divided into the following sections: (1) Title page, (2) Abstract and Keywords, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, (7) Acknowledgements, (8) Authors contribution, (9) References, (10) Figures' legend, (11), Tables and (12) Appendices. Figures should be submitted in separate files using JPEG or TIF format.
- Prepare your manuscript text using a Word processing package (save in .doc or .rtf format NOT .docx). Submissions of text in the form of PDF files are not permitted.

### COVER LETTER

A covering letter signed by corresponding author should provide full contact details (include the address, telephone number, fax number, and Email address). Please make clear that the final manuscript has been seen and approved by all authors, and that the authors accept full responsibility for the design and conduct of the study, had access to the data, and controlled the decision to publish. There should also be a statement that the manuscript is not under submission elsewhere and has not been published before in any form.

### AUTHORSHIP

As stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, credit for authorship requires substantial contributions to: (a) conception and design, or analysis and interpretation of data; (b) the drafting of the article or critical revision for important intellectual content and (c) final approval of the version to be published. Authors should meet

conditions a, b and c. All authors must sign authorship form attesting that they fulfill the authorship criteria. Your submitted manuscript will not be processed unless this form is sent. There should be a statement in manuscript explaining contribution of each author to the work. Those contributors who did not fulfill authorship criteria should be listed in acknowledgments.

Any change in authorship after submission must be approved in writing by all authors.

### ASSURANCES

In appropriate places in the manuscript please provide the following items:

- If applicable, a statement that the research protocol was approved by the relevant institutional review boards or ethics committees and that all human participants gave written informed consent
- The source of funding for the study
- The identity of those who analyzed the data
- Financial disclosure or a statement indicating "None" is necessary.

### TITLE PAGE

With the manuscript, provide a page giving the title of the paper; titles should be concise and descriptive (not declarative). Title page should include an abbreviated running title of 40 characters, the names of the authors, including the complete first names and no more than two graduate degrees, the name of the department and institution in which the work was done, the institutional affiliation of each author. The name, post address, telephone number, fax number, and Email address of the corresponding author should be separately addressed. Any grant support that requires acknowledgment should be mentioned on this page. Word count of abstract and main text as well as number of tables and figures and references should be mentioned on title page. If the work was derived from a project or dissertation, its code should also be stated. For clinical trials, a registry number like Iranian Registry of Clinical Trials (IRCT) should also be provided.

**Affiliation model:** Academic Degree, Department, Institute, City, Country

**Example:** Associate Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

## ABSTRACT

Provide on a separate page an abstract of not more than 300 words. This abstract should consist of four paragraphs, labeled **Background, Methods, Results, and Conclusion**. They should briefly describe the problem being addressed in the study, how the study was performed, the salient results, and what the authors conclude from the results, respectively. Three to 10 keywords may be included. Keywords are preferred to be in accordance with MeSH terms. Find MeSH terms: <http://www.ncbi.nlm.nih.gov/mesh>

## CONFLICT OF INTEREST

Authors of research articles should disclose at the time of submission any financial arrangement they may have with a company whose product is pertinent to the submitted manuscript or with a company making a competing product. Such information will be held in confidence while the paper is under review and will not influence the editorial decision, but if the article is accepted for publication, a disclosure will appear with the article.

Because the essence of reviews and editorials is selection and interpretation of the literature, the *Journal* expects that authors of such articles will not have any significant financial interest in a company (or its competitor) that makes a product discussed in the article.

## REVIEW AND ACTION

Submitted papers will be examined for the evidence of plagiarism using some automated plagiarism detection service. Manuscripts are examined by members of the editorial staff, and two thirds are sent to external reviewers. We encourage authors to suggest the names of possible reviewers, but we reserve the right of final selection. Communications about manuscripts will be sent after the review and editorial decision-making process is complete. After acceptance, editorial system makes a final language and scientific edition. No substantial change is permitted by authors after acceptance. It is the responsibility of corresponding author to answer probable questions and approve final version.

## COPYRIGHT

Isfahan Cardiovascular research Institute (ICRI) is the owner of all copyright to any original work published by the ARYA Journal. Authors agree to execute copyright transfer forms as requested with respect to their contributions accepted by the Journal. The ICRI have the right to use, reproduce, transmit, derive works from, publish, and distribute the contribution, in the *Journal* or otherwise, in any form or medium. Authors will not use or authorize the

use of the contribution without the Journal Office' written consent

## JOURNAL STYLE

Use normal page margins (2.5 cm), and double-space throughout.

### Tables

Double-space tables and provide a title for each.

### Figures

Figures should be no larger than 125 (height) x 180 (width) mm (5 x 7 inches) and should be submitted in a separate file from that of the manuscript. The name of images or figures files should be the same as the order that was used in manuscript (fig1, fig2, etc.). Only JPEG, TIF, GIF and EPS image formats are acceptable with CMYK model for colored image at a resolution of at least 300 dpi. Graphs must have the minimum quality: clear text, proportionate, not 3 dimensional and without disharmonic language. Electron photomicrographs should have internal scale markers.

If photographs of patients are used, either the subjects should not be identifiable or the photographs should be accompanied by written permission to use them. Permission forms are available from the Editorial Office.

Medical and scientific illustrations will be created or recreated in-house. If an outside illustrator creates the figure, the *Journal* reserves the right to modify or redraw it to meet our specifications for publication. The author must explicitly acquire all rights to the illustration from the artist in order for us to publish the illustration. Legends for figures should be an editable text as caption and should not appear on the figures.

### References

The Vancouver style of referencing should be used. References must be double-spaced and numbered as superscripts consecutively as they are cited. References first cited in a table or figure legend should be numbered so that they will be in sequence with references cited in the text at the point where the table or figure is first mentioned. List all authors when there are six or fewer; when there are seven or more, list the first six, then "et al." In the following some examples are listed:

1. McLaughlin TJ, Aupont O, Bambauer KZ, Stone P, Mullan MG, Colagiovanni J, et al. Improving psychologic adjustment to chronic illness in cardiac patients. The role of depression and anxiety. *J Gen Intern Med* 2005; 20(12): 1084-90.
2. Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. 7<sup>th</sup> ed. Philadelphia, PA: Elsevier Health Sciences; 2007. p. 1976, 1981, 1982.

3. Gaston M. The psychological care of patients following a myocardial infarction [Online]. 2003; Available from: URL: <http://www.nursingtimes.net/the-psychological-care-of-patients-following-a-myocardialinfarction/199464.article/>

### Units of Measurement

Authors should express all measurements in conventional units, with Système International (SI) units given in parentheses throughout the text. Figures and tables should use conventional units, with conversion factors given in legends or footnotes. In accordance with the Uniform Requirements, however, manuscripts containing only SI units will not be returned for that reason.

### Abbreviations

Except for units of measurement, abbreviations are discouraged. Consult *Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers* (Sixth edition. New York: Cambridge University Press, 1994) for lists of standard abbreviations. Except for units of measurement, the first time an abbreviation appears, it should be preceded by the words for which it stands.

### Drug Names

Generic names should generally be used except for studies on comparative effects of different brands. When proprietary brands are used in research, include the brand name and the name of the manufacturer in parentheses in the Methods section.

**For any more detail about the writing style for your manuscripts refer to:**

**<http://www.icmje.org>**

**Try to prepare your manuscript in accord with the scientific writing checklists available in EQUATOR Network:**

**<http://www.equator-network.org>**

### AFTER YOUR SUBMISSION

When a manuscript arrives to ARYA office, a staff member checks it to make sure that all materials required for submission are included. If everything is present, the article is registered in office and referred to the managing editor.

The first step the manuscript makes on its editorial journey is on the desk of the editor-in-chief, who reviews each submission (in his absence this is done by the managing editor) and decides on the basis of its general content whether it is appropriate even for consideration for publication. Each of the remaining scientific manuscripts is assigned to an associate editor with expertise in the subject area covered by the study, who makes an independent assessment of

the value and validity of the paper. If the associate editor believes that even with favorable reviews the paper would not be published because it lacks novelty or importance, or if he/she spots a major flaw in experimental design, performance or statistical analysis the manuscript is returned to the authors.

If, on the other hand, the associate editor believes that the paper may merit publication, it is sent to two of our outside **reviewers**. They are asked to provide a frank evaluation of the *scientific validity of the manuscript, insight into its freshness, clinical impact, and timeliness, and an overall opinion* of its worthiness for publication. This is the key step in manuscript evaluation. As editors, we are grateful to all our reviewers for their continued contribution to the rating process. We are careful not to refer to them as "referees," which would suggest that the decision to publish a paper rests entirely with them. It does not. The reviewers provide critiques and advice that the editorial staff uses in making decisions. But we, **ARYA editorial board**, make the decisions. When both outside reviews are returned, the associate editor then assesses the manuscript again, along with the comments of the reviewers. She may seek additional opinions from other reviewers, or may discuss the manuscript at a meeting of the entire editorial staff. At this meeting a decision is made either to reject the paper or to proceed further editorial consideration, including, if appropriate, a formal review of the statistical or experimental methods. In some cases, the editorial staff may recommend additional review by outside reviewers. On completion of this process, the manuscript is usually returned to its authors along with a letter inviting them to revise it and to respond to certain questions. When all the requested information has been received, the manuscript is reconsidered by an associate editor, and it may be discussed again with other members of the editorial staff. We then make our final decision to *accept* or *reject* the paper.

We recognize that the peer-review process is not perfect, but we earnestly believe that it is the best way to select and publish the most important medical research. Peer review is labor-intensive and sometimes *time-consuming*, but without it physicians themselves would have to assess the validity of new medical research and decide when to introduce new treatments into practice.

We do all our efforts to finalize this process in a *3 to 4 months* period for each manuscript.

We understand the importance of a submitted manuscript to its authors. **We invite you to submit your best research to us; we will treat it with respect, and you can follow it on its journey.**

## Type of Articles Considered to be Published in *ARYA Atherosclerosis Journal*

ARYA Atherosclerosis is a bimonthly peer-reviewed scientific Journal providing academically sound, clinically practical information for physicians, medical scientists and health care providers. ARYA Atherosclerosis is published by Isfahan Cardiovascular Research Institute. Journal editors review articles in fields of atherosclerosis, its risk factors and related diseases.

### ORIGINAL RESEARCH

- **Original Articles** are scientific reports of the results of original clinical research. The text is limited to 3000 words (excluding abstracts and references), with a structured abstract, a maximum of 5 tables and figures (total), and up to 30 references.
- **Special Articles** include data and generally focus on areas such as economic policy, ethics, law, or health care delivery. The text is limited to 3000 words, with an abstract, a maximum of 5 tables and figures (total), and up to 30 references.
- **Qualitative Researches** focus to clear underlying reasons, opinions, and motivations. It helps to develop ideas or hypotheses for potential quantitative research. The text is limited to 3500 words, with an abstract, a maximum of 5 tables and figures (total), and up to 30 references.
- **Short Communication Articles** are short scientific entities often dealing with methodological problems or with byproducts of larger research projects and are suitable for the presentation of research that extends previously published research. A short communication is for a concise, but independent report representing a significant contribution to cardiology. Short communication is not intended to publish preliminary results. It should be no more than 1000 words, and could include 2 figures or tables. It should have at least 15 references. Short communications are also sent to peer review.

### CLINICAL CASES

- **Brief Reports** usually describe one to three patients or a single family. The text is limited to 1000 words, a maximum of 5 tables and figures (total), and up to 15 references. It does not include an abstract.
- **Clinical Problem-Solving** manuscripts consider the step-by-step process of clinical decision making. Information about a patient is presented to an expert clinician or clinicians in stages (in the manuscript this

is indicated in **boldface** type) to simulate the way such information emerges in clinical practice.

The clinician responds (regular type) as new information is presented, sharing his or her reasoning with the reader. The text should not exceed 2500 words, and there should be no more than 20 references. The use of clinical illustrative materials, such as x-ray films, is encouraged.

### REVIEW ARTICLES

All review articles undergo the same peer-review and editorial process as original research reports. The text is limited to 7000 words, with unlimited number of figures, tables, and references.

- **Conflicts of Interest:** Because the essence of review articles is selection and interpretation of the literature, the **ARYA Atherosclerosis Journal** expects that the authors of such articles will not have a significant financial association with a company (or its competitor) that makes a product discussed in the article.
- **Clinical Practice** articles are evidence-based reviews of topics relevant to practicing physicians, both primary care providers and specialists. Articles in this series should include the following sections: clinical context, strategies and evidence, areas of uncertainty, guidelines from professional societies, and recommendations from the authors. The text does not include an abstract.
- **Current Concepts** articles focus on clinical topics, including those in specialty areas but of wide interest.
- **Drug Therapy** articles detail the pharmacology and use of specific drugs or classes of drugs, or the various drugs used to treat particular diseases.
- **Mechanisms of Disease** articles discuss the cellular and molecular mechanisms of diseases or categories of diseases.
- **Medical Progress** articles provide scholarly, comprehensive overviews of important clinical subjects, with the principal (but not exclusive) focus on developments during the past five years. Each

article details how the perception of a disease, disease category, diagnostic approach, or therapeutic intervention has evolved in recent years.

## OTHER SUBMISSIONS

- **Editorials** usually provide commentary and analysis concerning an article in the issue of the *Journal* in which they appear. They may include an illustration or table. They are nearly always solicited, although occasionally, unsolicited editorials may be considered. Editorials are limited to 1200 words, with up to 15 references.
- **Perspectives** are also nearly always solicited, but we are willing to consider unsolicited proposals. Perspectives provide background and context for an article in the issue in which they appear. Perspectives are limited to 800 words and usually include an illustration. There are no reference citations.
- **Sounding Board** articles are opinion essays. They are similar to editorials but not tied to a particular article. They often present opinions on health policy issues and are normally unsolicited. The text is limited to 2000 words.
- **Clinical Implications of Basic Research** articles discuss single papers from preclinical journals. The purpose is to explain the findings and comment on their possible clinical applications in fewer than 1000 words. There may be one figure and up to four references. We do not consider unsolicited manuscripts in this category.
- **Images in Clinical Medicine** are classic images of common medical conditions. Visual images are

an important part of much of what we do and learn in medicine. This feature is intended to capture the sense of visual discovery and variety that physicians experience. Images in Clinical Medicine are not intended as a vehicle for case reports.

- **Special Reports** are miscellaneous articles of special interest to the medical community. They are limited to 2700 words.
- **Legal Issues in Medicine** are nearly always solicited, but *Journal* is willing to consider unsolicited manuscripts or proposals for manuscripts.
- **Health Policy Reports** are nearly always solicited, but *Journal* is willing to consider unsolicited manuscripts or proposals for manuscripts.
- **Occasional Notes** are accounts of personal experiences or descriptions of material from outside the usual areas of medical research and analysis.
- **Book Reviews** are generally solicited.
- **Letters to the Editor:** Letters to the Editor are considered for publication (subject to editing and abridgment) provided they do not contain material that has been submitted or published elsewhere. The text, not including references, must not exceed 250 words if it is in reference to a recent *Journal* article, or 500 words in all other cases. A letter must have no more than 5 references and 1 figure or table. It must not be signed by more than three authors. Letters referring to a recent *Journal* article must be received within three weeks of its publication.

The publication fees of ARYA Atherosclerosis Journal

Type of the article	Permitted word count*	The payment fee in Iranian Rial (IRR)	The payment fee for each 500 excess words (IRR)
Letter to the Editor	500	-	-
Clinical Case	1000	2,000,000	400,000
Short Communication	1000	2,000,000	400,000
Original Article	3000	3,500,000	400,000
Qualitative Research	3500	3,500,000	400,000
Review Article	7000	3,500,000	400,000

\* All the words of the article containing the references; each table is considered as 300 words.

There will be a 50% discount of publication fee if both the first and the corresponding author are affiliated to Isfahan University of Medical Sciences (IUMS).

## Table of Contents

---

---

### Editorial

- 1. Orthopedic problems: An underestimated hidden risk factor for development and progression of atherosclerosis; An inconspicuous joint link**  
*Mohaddeseh Behjati* .....115-117

### Original Article(s)

- 2. Lipid peroxidation and antioxidant enzymes activity in controlled and uncontrolled Type 2 diabetic patients**  
*Mahnaz Zarei, Zahra Farahnak, Mohammad Javad Hosseinzadeh-Attar, Mohammad Hassan Javanbakht, Payam Hosseinzadeh, Hoda Derakhshanian, Payam Farahbakhsh-Farsi, Mahmoud Djalali* .....118-123
- 3. Comparison of health-related quality of life after percutaneous coronary intervention and coronary artery bypass surgery**  
*Razieh Yazdani-Bakhsh, Mehdi Javanbakht, Masoumeh Sadeghi, Atefeh Mashayekhi, Hossein Ghaderi, Katayoun Rabiei*.....124-131
- 4. Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction for prediction of cerebrovascular event in an Iranian cohort study: The Isfahan Cohort Study**  
*Davoud Kazemi-Saleh, Pooya Koosha, Masoumeh Sadeghi, Nizal Sarrafzadegan, Reza Karbasi-Afshar, Mansoureh Boshtam, Shahram Oveis-Gharan* .....132-137
- 5. What is role of sex and age differences in marital conflict and stress of patients under Cardiac Rehabilitation Program?**  
*Saeid Komasi, Mozghan Saeidi* .....138-145
- 6. Predicting metabolic syndrome using decision tree and support vector machine methods**  
*Farzaneh Karimi-Alavijeh, Saeed Jalili, Masoumeh Sadeghi* .....146-152

### Case Report(s)

- 7. Reversible left bundle branch block should be mentioned in cardiac resynchronization therapy; A clinical case report**  
*Ali Vasheghani-Farahani, Masih Tajdini, Seyed Abolfazl Mohsenizadeh, Seyed Mohammad Reza Hosseini*  
.....153-155

### Letter to Editor(s)

- 8. Normal range of bleeding time in west of Iran**  
*Hassan Mansouritorghabeh* .....156-157

# Orthopedic problems: An underestimated hidden risk factor for development and progression of atherosclerosis; An inconspicuous joint link

**Mohaddeseh Behjati<sup>(1)</sup>**

**Editorial**

*Date of submission:* 12 Nov 2014, *Date of acceptance:* 13 May 2015

## Introduction

Regular leisure time and occupational physical activity exerts beneficial effects on cardiovascular health.<sup>1</sup> Healthy life style and physical activity behaviors diminish overall rate of coronary artery disease (CAD) among both female and male gender.<sup>2</sup> Favorable effects of physical activity have been proven concerning cardiovascular disease (CVD) morbidity and mortality.<sup>3</sup> It improves cardiovascular function and compliance. Even modest physical activity minimizes the risk of CVD occurrence.<sup>4</sup>

Regular exercise impacts numerous health benefits in older people including improvement in blood pressure, osteoarthritis, osteoporosis, diabetes mellitus, lipid profile, CVD, neurocognition function, mood and overall morbidity and mortality.<sup>3</sup> Physical activity has beneficial dose-dependent effects on blood pressure via reaching a plateau level.<sup>5</sup> Cardioprotective effects of life-long physical activity and endurance exercise against cardiac insults are well-elucidated in both young and old age population.<sup>6</sup> Beneficial impacts of physical activity occur at various cellular organizations as mitochondria. Regular physical activity accompanies with cessation of cigarette smoking, decreased consumption of saturated fatty acids, reaching and maintenance of ideal body weight and decreased stress level which are all involved in achievement of cardiovascular health.<sup>6</sup>

Our ancestors were obligated to exert higher levels of physical activity in order to survive and that partly explains lower prevalence of this human-made disease in ancient nations. Modern life brought enhanced sitting time by facilitating achievement of daily requirements. Voluntary

physical inactivation is a threat for majority of population, but by increasing the percentage of old age population, the ratio of people with involuntary physical inactivity will enhance dramatically. Physical activity behaviors might exist but converting it into action needs proper functioning of neuromusculoskeletal system. Therefore, this unintentional physical inactivity prohibits deriving cardiovascular benefits from physical activity. Thus, the aim of this article is to scheme an overview on inconspicuous link between orthopedic problems and CVD.

Orthopedic disorders bring great limitation for accomplishment of regular physical activity both in young and old people. Orthopedic problems are predisposing factors for lack of proper physical activity and alarming increase in sedentary habits. Considering the established association between physical activity and cardiovascular health, hints towards regular physical activity renders provocation of development and progression of atherosclerosis. Primarily, orthopedic insufficiency might prevent access to therapeutic pills and other therapeutic interventions. Thus, poor adherence and non-adherence to medical advises as effort to attend in follow-up sessions is another side of the coin. Depression related to impaired locomotion is also contributing to the progression of CVD.<sup>7</sup>

Since some of orthopedic disorders occur in the setting of underlying inflammatory conditions, the underlying inflammatory background bridges the gap between healthy and unhealthy cardiovascular system.<sup>8</sup> The delicate inter-relationship between vitamin D on both CVD and vitamin-D-deficiency-related bone disorders are also proposed. Heart failure is

1- Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran  
Correspondence to: Mohaddeseh Behjati, Email: behjati@med.mui.ac.ir

considered as an increased risk factor for development of subsequent orthopedic bone fracture.<sup>9</sup>


This is not the whole story. Orthopedic disorders are associated with CVDs in other ways. Some side effects of orthopedic problems are the leading causes of CVD, as occurrence of venous thromboembolism (VTE) after orthopedic surgeries or bed rest. Indeed, adverse side effects of applied medications as non-steroid anti-inflammatory drugs (NSAIDs) and corticosteroids on cardiovascular system health should not be neglected. Figure 1 is schematic view for demonstration of links between orthopedic disorders and cardiovascular diseases.

Obviously, this could not be a primary risk factor for CVD. Since orthopedic disorders are mainly happening in old age as the same with CVD, these orthopedic problems could be considered as risk factor or even co-risk factors for development and progression of CVD. In better

word, orthopedic problems could be considered as a secondary or tertiary risk factor for the onset and follow up of CAD. In brief, the current state of orthopedic disorders as secondary or tertiary risk factor for CVD is not definite due to the lack of clinical trials in this regard. Involuntary physical inactivity is not merely related to orthopedic problems, but each condition which compromise bodily locomotion should be considered as a risk factor for CVD. Considering this hidden risk factor, physicians should try to dampen the negative effects of this negative risk factor. But practically, the general advice of "having moderate intensity amounts of regular physical activity as walking through the park, running or cycling" should be avoided. The type of physical interventions should be personalized and physicians should advocate patients to find practical exercise prescription per case.

### Conflict of Interests

Authors have no conflict of interests.



**Figure 1.** The schematic view for demonstration of links between orthopedic disorders and cardiovascular diseases (CVD)  
NSAIDs: Non-steroid anti-inflammatory drugs

## References

1. Li J, Siegrist J. Physical activity and risk of cardiovascular disease-a meta-analysis of prospective cohort studies. *Int J Environ Res Public Health* 2012; 9(2): 391-407.
2. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation* 2003; 107(24): 3109-16.
3. Fogelholm M. Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. *Obes Rev* 2010; 11(3): 202-21.
4. Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. *Circulation* 2006; 113(4): 499-506.
5. Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH. Beyond salt: Lifestyle modifications and blood pressure. *Eur Heart J* 2011; 32(24): 3081-7.
6. Ascensao A, Lumini-Oliveira J, Oliveira PJ, Magalhaes J. Mitochondria as a target for exercise-induced cardioprotection. *Curr Drug Targets* 2011; 12(6): 860-71.
7. Huffman JC, Beach SR, Suarez L, Mastromauro CA, DuBois CM, Celano CM, et al. Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial. *Contemp Clin Trials* 2013; 36(2): 488-501.
8. van Sijl AM, van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Smulders YM, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2015; 74(1): 119-23.
9. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. *Circulation* 2008; 118(19): 1946-52.

**How to cite this article:** Behjati M. Orthopedic problems: An underestimated hidden risk factor for development and progression of atherosclerosis; An inconspicuous joint link. *ARYA Atheroscler* 2016; 12(3): 115-7.

## Lipid peroxidation and antioxidant enzymes activity in controlled and uncontrolled Type 2 diabetic patients

Mahnaz Zarei<sup>(1)</sup>, Zahra Farahnak<sup>(1)</sup>, Mohammad Javad Hosseinzadeh-Attar<sup>(2)</sup>,  
Mohammad Hassan Javanbakht<sup>(3)</sup>, Payam Hosseinzadeh<sup>(4)</sup>, Hoda Derakhshanian<sup>(1)</sup>,  
Payam Farahbakhsh-Farsi<sup>(3)</sup>, Mahmoud Djalali<sup>(5)</sup>

### Original Article

#### Abstract

**BACKGROUND:** This study was designed to compare lipid peroxidation and antioxidant enzymes activity in Type 2 diabetes patients with good or weak glycemic control.

**METHODS:** In this case-control study, 62 Type 2 diabetic patients with glycated hemoglobin (HbA1c) between 6 and 8 were enrolled as the controlled group and 55 patients with HbA1c > 8 were selected as an uncontrolled group. Patients were all referred to Iranian Diabetes Association in Tehran, Iran, from 2010 onward. Groups were chosen by convenience sampling and were matched based on age, sex and duration of disease. Demographic questionnaire, two 24-hour food recall, HbA1c, insulin, malondialdehyde (MDA), superoxide dismutase (SOD), and catalase were measured in blood samples. Data were analyzed by Food Processor II and SPSS software.

**RESULTS:** A mean daily consumption of energy, carbohydrate, protein, and fat was not significantly different between two groups. MDA in the uncontrolled group was significantly higher than controlled group ( $2.03 \pm 0.88$  vs.  $1.65 \pm 1.01$  nmol/ml;  $P = 0.030$ ). A mean SOD was slightly higher in the uncontrolled group comparing to the control group ( $843.3 \pm 101.9$  vs.  $828.0 \pm 127.3$  U/g Hb;  $P = 0.400$ ).

**CONCLUSION:** These data suggest that MDA as a lipid peroxidation indicator is higher in uncontrolled diabetes probably due to chronic high blood sugar followed by higher oxidative stress.

**Keywords:** Antioxidant, Lipid Peroxidation, Diabetes Mellitus

*Date of submission:* 17 Jun 2014, *Date of acceptance:* 9 Apr 2016

#### Introduction

Diabetes mellitus, one of the most common endocrine disorders, is known as high fasting blood sugar (FBS) more than 126 mg/dl threshold.<sup>1</sup> Hyperglycemia is a major factor in the development of diabetic complications.<sup>2,4</sup> However, the mechanism by which these changes occur is not clear. Glycosylated hemoglobin (HbA1c), which reflects long-term (2-3 months) control of blood glucose, is more reliable and valid compared with the FBS.<sup>5</sup>

HbA1c < 7% is considered as well diabetes control according to the American Diabetes Association. The association has advised physicians and patients that when the HbA1c levels exceed 8% may be related to developing of diabetes micro- and macro-vascular complications,<sup>6</sup> and additional medical therapies are needed.<sup>7</sup> Hence, the HbA1c levels of 8% were considered in this study as cut-off point for allocating patients into two groups (controlled and uncontrolled). Chronically high blood sugar

1- Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

2- Associate Professor, Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

3- Assistant Professor, Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

4- Department of Nutrition and Biochemistry, The International Campus, Tehran University of Medical Sciences, Kish, Iran

5- Professor, Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

Correspondence to: Mahmoud Djalali, Email: mjalali87@yahoo.com

can be seen in patients with diabetes, and this may increase glycosylation and peroxidation processes which may lead to oxidative stress and resulting changes in structure and function of proteins and lipids.<sup>8</sup> In comparison with other cells, red blood cells are more prone to oxidative damage due to the high levels of iron and polyunsaturated fatty acids and also their role in oxygen transportation.<sup>9</sup> Lipid hydroperoxides are degraded into the harmful aldehydes, such as malondialdehyde (MDA), in the presence of iron and copper ions. Therefore, MDA is considered as an indicator of lipid peroxidation and its value is used as indirect method of measuring free radicals.<sup>10</sup>

Superoxide dismutase (SOD) and catalase are important antioxidant enzymes which play a role in oxidant defense of body and often as the first line of defense against oxidative crisis.<sup>11</sup>

Some studies have previously evaluated the status of MDA and antioxidant enzymes in diabetic and healthy individuals.<sup>12-14</sup> However, this study was designed and performed for the first time to compare lipid peroxidation and antioxidant enzymes in Type 2 diabetes patients with good or weak control.

## Materials and Methods

In this study, 62 Type 2 diabetic patients with HbA1c between 6 and 8 were enrolled as the controlled group and 55 patients with HbA1c > 8 were selected as uncontrolled group. Patients were all referred to Iranian Diabetes Association in Tehran, Iran, from 2010 onward. Groups were chosen by convenience sampling and were matched based on age, sex and duration of disease. A sample size of at least 50 patients in each group was estimated according to previous reports on leptin and adiponectin with the assumption of 80% power, and a 0.05 level of significance. The level of body mass index (BMI) was not different between groups. Inclusion criteria included fasting blood glucose above 126 mg/dl, HbA1c levels more than 6, the minimum age of 40 years, at least 3 years of diagnosed diabetes, consumption of oral hypoglycemic drugs, and consent for cooperation in this research study. Meanwhile, the exclusion criteria

were insulin injections, supplementation with vitamins A, C, E and omega-3, history of hepatic, renal, cardiovascular, thyroid, or respiratory diseases. All the process was in the patient privacy and in accordance with Declaration of Helsinki-Ethical Principles for Medical Research.

Demographic data, including age, sex, and duration of diabetes, were recorded. Weight was measured using a digital scale (803, Seca Clara, Germany) with an accuracy of 100 g, in light clothes and without shoes. Height was measured without shoes using a stadiometer (206, Seca, Germany) with an accuracy of 0.1 cm. Hip and waist circumferences were measured using a measuring tape (201, Seca, Germany) with an accuracy of 0.1 cm. BMI was calculated using these recorded values [weight (kg)/height<sup>2</sup> (m)]. In addition, two 24-hour food recall questionnaires were completed by an expert nutritionist. Then, the average daily intakes of calorie, protein, carbohydrate, and fat were calculated. After recording the necessary information and before taking oral hypoglycemic drugs, 10 ml of venous blood was taken in 12-hours fasting state by a laboratory expert. Samples were centrifuged in 3000 rpm for 10 minutes. Blood glucose, HbA1c, insulin, MDA, SOD, and catalase were then measured in blood samples. HbA1c was measured by an ion exchange chromatography using a Nycocard® Reader II instrument (Catalog ref 1042184, Axis-Shield poC AS, Oslo, Norway) on ethylenediaminetetraacetic acid anticoagulated samples; insulin was measured using insulin kits and serum MDA values were determined by the spectrophotometric method described by Satoh using thiobarbituric acid. This measurement is based on the reaction of MDA with thiobarbituric acid to form 1:2 adduct, which has a stable pink color that absorbs maximally at 532 nm.<sup>15</sup> Measurements of SOD activity in erythrocytes were done spectrophotometrically using Randox Kit (Cat # SD125, Crumlin, UK). Catalase activity was determined using spectrophotometric method and measuring the decrease in hydrogen peroxide absorbance at 240 nm wavelength.<sup>16</sup>

**Table 1.** Demographic characteristics and hematological indices in controlled and non-controlled Type 2 diabetes groups

Variable	Group		Independent sample t-test
	Non-controlled Type 2 diabetes (n = 55)	Controlled Type 2 diabetes (n = 62)	
	Mean ± SD	Mean ± SD	
Age (year)	54.27 ± 7.53	56.82 ± 7.61	0.080
Weight (kg)	74.16 ± 10.94	72.34 ± 10.61	0.360
BMI (kg/m <sup>2</sup> )	29.49 ± 4.34	27.65 ± 3.89	0.080
Duration of diabetes (year)	10.89 ± 6.41	9.94 ± 6.75	0.430
Insulin (μU/ml)	13.53 ± 9.74	8.76 ± 7.17	0.510
Insulin resistance	6.96 ± 5.67	2.95 ± 2.64	< 0.001
FBS (mg/dl)	214.36 ± 68.22	136.15 ± 40.59	< 0.001
HbA1c (%)	8.88 ± 0.64	7.09 ± 0.58	< 0.001

The controlled group (62 patients with  $6 < \text{HbA1c} \leq 8$ ) and uncontrolled group (55 patients with  $\text{HbA1c} > 8$ ); BMI: Body mass index; FBS: Fasting blood sugar; HbA1c: Glycated hemoglobin; SD: Standard deviation

A SPSS software for Windows (version 13.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis of data. After normalizing the distribution of data by log transformation, independent t-test was used for comparing the means of quantitative variables in two groups. Furthermore, the nutritional data were analyzed by Food Processor FP II (version 2, Esha Research, salem, OR).  $P = 0.050$  or less were considered as the statistically significant difference.

## Results

In this study, 117 non-insulin dependent Type 2 diabetic patients of both sexes that had passed at least 3 years of diabetes onset from Iran Diabetes Association were involved. Participants were divided into the well-controlled (62 patients: 27 female, 35 male) and uncontrolled (55 patients: 34 female, 21 male) group. Of all participants, 52.1% (61 patients) were female and 47.9% (56 patients) were male. Patients' characteristics are shown in table 1. Mean MDA, catalase, and SOD values in the two groups are given in table 2. The table 2 indicates that MDA in the uncontrolled diabetes group was

significantly higher than controlled diabetes group ( $P = 0.030$ ). Mean SOD was slightly higher in the uncontrolled group comparing to the control group but was not statistically significant ( $P = 0.480$ ). Catalase was not much different between the two groups ( $P = 0.940$ ). According to table 3, the most important variable affecting the level of catalase is protein intake. However, no variable had statistically significant effect on the level of SOD. Mean daily consumption of energy, carbohydrate, protein, and fat was not significantly different between well controlled and uncontrolled diabetes groups.

## Discussion

Results obtained in this study suggest that MDA in uncontrolled diabetes group was significantly higher than the control group. In some studies, elevated HbA1c in patients with diabetes was associated with increased lipid peroxidation, while such a relationship has not been seen in some other studies.<sup>17-19</sup> Ahmed et al.<sup>20</sup> have been found that high blood glucose levels lead to increased oxidative stress, and consequently, MDA levels may increase.

**Table 2.** Comparison of mean malondialdehyde (MDA), catalase and superoxide dismutase between controlled and non-controlled Type 2 diabetes groups

Variable	Group		Independent sample t-test
	Non-controlled Type 2 diabetes (n = 55)	Controlled Type 2 diabetes (n = 62)	
	Mean ± SD	Mean ± SD	
MDA (nmol/ml)	2.01 ± 0.88	1.63 ± 1.01	0.030
Catalase (k/gHb)	205.12 ± 47.25	206.11 ± 80.49	0.940
SOD (U/gHb)	843.30 ± 101.90	828.00 ± 127.30	0.480

MDA: Malondialdehyde; SOD: Superoxide dismutase, Hb: Hemoglobin; SD: Standard deviation

**Table 3.** Comparison of mean energy, quantity and percent of carbohydrate, protein and fat intakes between controlled and non-controlled Type 2 diabetes groups

Variable	Group		Independent sample t-test
	Non-controlled Type 2 diabetes (n = 55)	Controlled Type 2 diabetes (n = 62)	
	Mean ± SD	Mean ± SD	P
Energy (kcal)	1330.22 ± 442.37	1416.21 ± 447.26	0.300
Carbohydrate (g)	196.37 ± 72.62	211.96 ± 80.02	0.270
Carbohydrate (%)	58.88 ± 8.16	59.56 ± 8.39	0.660
Protein (g)	53.08 ± 17.74	59.03 ± 19.72	0.090
Protein (%)	16.23 ± 3.12	16.97 ± 3.82	0.260
Fat (g)	40.71 ± 19.92	41.37 ± 17.16	0.850
Fat (%)	27.48 ± 8.72	26.39 ± 7.07	0.460

SD: Standard deviation

Seghrouchni et al.<sup>21</sup> have found that patients with Type 2 diabetes had a higher thiobarbituric acid reactive substances value than those with Type 1 diabetes. They have claimed that patients with Type 2 diabetes are more extendedly exposed to oxidative stress. In this study, the rate of catalase activity was not much different in the two groups ( $206.11 \pm 80.49$  vs.  $205.12 \pm 45.25$ ). In Ahmed et al.<sup>20</sup> study the activity of catalase and SOD were significantly higher in the diabetic group than the healthy group.

Colak et al.<sup>22</sup> showed that anti-oxidative defense reduces in Type 2 diabetics, which negatively correlates with glucose concentrations and duration of diabetes and cardiovascular complications. In another study aiming to evaluate the effect of blood glucose control on catalase, catalase levels in patients with diabetes (HbA1c more than 8%), did not differ from healthy controls. However, after 3 months of hypoglycemic drugs consumption, catalase levels in patients with diabetes was less than the control group.<sup>20</sup>

In this study, subjects in both groups (controlled and uncontrolled diabetes) have been taking hypoglycemic agents (metformin or glibenclamide) and the strong sweeper effects of these drugs may have diminished the difference of catalase amount between the two groups.

Increase of free radicals in diabetes may increase antioxidant enzyme activities. In addition, high blood glucose can combine with the protein enzymes so that in patients with diabetes extracellular SOD is highly glycosylated comparing to healthy subjects.<sup>23</sup> Although, in

some studies antioxidant enzymes such as SOD were inversely correlated with HbA1c, SOD in the present study was directly correlated with the level of FBS, HbA1c, and insulin resistance. However, these correlations were not statistically significant. In some other studies, no correlation was seen between SOD, FBS, and HbA1c. In present study higher SOD in uncontrolled diabetes group was an indicator of higher oxidative stress.

Other studies have evaluated the antioxidant status and SOD activity in patients with diabetes compared with healthy controls, but they did not found any significant differences between groups in terms of SOD activity.<sup>22</sup>

Furthermore, no significant relationship was observed between nutritional factors, MDA and SOD. It was previously reported that intake of antioxidant supplements can reduce reactive oxygen species and free radicals and may result in reducing lipid peroxidation.<sup>24</sup> In this study, vitamin supplements-such as vitamin A, C, E and omega-3 consumption-were among our exclusion criteria, so we had removed the effect of these confounding factors on the measurements and study results.<sup>25</sup> In this study, a mean percentage of protein intake was about 17% in both groups. The protein intake was the only nutritional factor which has affected the catalase level. The equal amount of protein intake in both groups was possibly one of the reasons that catalase was not so different between groups. This study encountered with a limited budget and sample

size. In future study, we can examine this variable with large sample size or with more sensitive indicator in diabetic patients.

### Conclusion

MDA (lipid peroxidation indicator) is higher in uncontrolled diabetes (HbA1c > 8) probably due to chronic high blood sugar, followed by long and high oxidative stress. Furthermore, SOD is also higher in uncontrolled diabetes which might be an indicator of greater vascular damage in this group.

### Acknowledgments

This study was granted by Tehran University of Medical Sciences and Health Services. We gratefully appreciate all persons who participated in this study.

### Conflict of Interests

Authors have no conflict of interests.

### References

- Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. *Nat Rev Endocrinol* 2012; 8(4): 228-36.
- Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. *Diabetes Care* 2008; 31(11): 2198-202.
- Izadi M, Fazel M, Karbasi-Afshar R, Saadat SH, Nasserri MH, Jonaidi-Jafari N, et al. Glycemic control in type 2 diabetes mellitus prevents coronary arterial wall infection. *ARYA Atheroscler* 2014; 10(3): 141-6.
- Nikkar B, Khosravi-Boroujeni H, Kolahdouzan M, Ghoreishyan M, Ebadi S, Mohamadzadeh A, et al. Is responsiveness to weight loss diets affected by family history of diabetes? *ARYA Atheroscler* 2014; 10(3): 164-8.
- Goldstein DE, Little RR, Lorenz RA, Malone JJ, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. *Diabetes Care* 2004; 27(7): 1761-73.
- Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, et al. Relationship between glycosylated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? *Diabetologia* 2009; 52(7): 1279-89.
- Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care* 2008; 31(Suppl 1): S61-S78.
- Chang CM, Hsieh CJ, Huang JC, Huang IC. Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus. *Acta Diabetol* 2012; 49(Suppl 1): S171-S177.
- Pandey KB, Rizvi SI. Biomarkers of oxidative stress in red blood cells. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2011; 155(2): 131-6.
- Monaghan P, Metcalfe NB, Torres R. Oxidative stress as a mediator of life history trade-offs: mechanisms, measurements and interpretation. *Ecol Lett* 2009; 12(1): 75-92.
- Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. *Free Radic Biol Med* 2009; 47(4): 344-56.
- Likidilid A, Patchanans N, Peerapatdit T, Sriratanasathavorn C. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients. *J Med Assoc Thai* 2010; 93(6): 682-93.
- Mancino R, di Pierro D, Varesi C, Cerulli A, Feraco A, Cedrone C, et al. Lipid peroxidation and total antioxidant capacity in vitreous, aqueous humor, and blood samples from patients with diabetic retinopathy. *Mol Vis* 2011; 17: 1298-304.
- Srivatsan R, Das S, Gadde R, Manoj-Kumar K, Taduri S, Rao N, et al. Antioxidants and lipid peroxidation status in diabetic patients with and without complications. *Arch Iran Med* 2009; 12(2): 121-7.
- Benzie IF. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. *Int J Food Sci Nutr* 1996; 47(3): 233-61.
- Aebi H. Catalase in vitro. *Methods Enzymol* 1984; 105: 121-6.
- Mawatari S, Saito K, Murakami K, Fujino T. Absence of correlation between glycosylated hemoglobin and lipid composition of erythrocyte membrane in type 2 diabetic patients. *Metabolism* 2004; 53(1): 123-7.
- Turk HM, Sevinc A, Camci C, Cigli A, Buyukberber S, Savli H, et al. Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. *Acta Diabetol* 2002; 39(3): 117-22.
- Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. *Chem Rev* 2011; 111(10): 5944-72.
- Ahmed FN, Naqvi FN, Shafiq F. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. *Ann N Y Acad Sci* 2006; 1084: 481-9.
- Seghrouchni I, Draï J, Bannier E, Riviere J,

- Calmard P, Garcia I, et al. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. *Clin Chim Acta* 2002; 321(1-2): 89-96.
22. Colak E, Majkic-Singh N, Stankovic S, Sreckovic-Dimitrijevic V, Djordjevic PB, Lalic K, et al. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. *Ann Med* 2005; 37(8): 613-20.
23. Arai K, Maguchi S, Fujii S, Ishibashi H, Oikawa K, Taniguchi N. Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. *J Biol Chem* 1987; 262(35): 16969-72.
24. Halliwell B. Free radicals and antioxidants-quo vadis? *Trends Pharmacol Sci* 2011; 32(3): 125-30.
25. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. *Nutrition* 2002; 18(10): 872-9.

**How to cite this article:** Zarei M, Farahnak Z, Hosseinzadeh-Attar MJ, Javanbakht MH, Hosseinzadeh P, Derakhshanian H, et al. **Lipid peroxidation and antioxidant enzymes activity in controlled and uncontrolled Type 2 diabetic patients.** *ARYA Atheroscler* 2016; 12(3): 118-23.

## Comparison of health-related quality of life after percutaneous coronary intervention and coronary artery bypass surgery

Razieh Yazdani-Bakhsh<sup>(1)</sup>, Mehdi Javanbakht<sup>(2)</sup>, Masoumeh Sadeghi<sup>(3)</sup>,  
Atefeh Mashayekhi<sup>(4)</sup>, Hossein Ghaderi<sup>(5)</sup>, Katayoun Rabiei<sup>(6)</sup>

### Original Article

#### Abstract

**BACKGROUND:** Health-related quality of life (HRQOL) evaluation is an important measure of the impact of the disease. As more people with coronary heart disease (CHD) live longer, doctors and researchers want to know how they manage in day to day life. It looked like adults with CHD had a decrease QOL. The aim of this study was to comparison of HRQOL of patients who underwent percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) and to assess its main determinants in the whole sample of coronary artery disease (CAD) patients.

**METHODS:** The study was carried out to estimate HRQOL of 109 patients who underwent invasive coronary revascularization [PCI (n = 75) and CABG (n = 34)]. We applied HRQOL after 6 months and 2 years in both groups and scores were compared. The HRQOL data were obtained using MacNew Heart Disease questionnaire with dimensions emotional, physical and social that estimated. Data entry and analysis were performed by SPSS.

**RESULTS:** A total MacNew scale in CABG and PCI group in 6 months after treatment were  $45.32 \pm 13.75$  and  $53.52 \pm 15.63$ , respectively ( $P = 0.010$ ). After 2 years HRQOL mean changed to  $51.176 \pm 14.80$  and  $49.55 \pm 16.22$ , respectively, in CABG and PCI group ( $P = 0.428$ ). Our results in within-group analysis showed total MacNew scale and its subscales were changed significantly after 2 years in CABG and PCI group's scores were detected. We found in the whole sample of CAD patients those who had a higher level of income and education and were not either overweight or obese experienced better HRQOL.

**CONCLUSION:** Our results showed that patients who underwent PCI experienced significantly higher HRQOL in 6 months after revascularization but over 24 months follow-up no difference was observed between the two groups.

**Keywords:** Quality of Life, Percutaneous Coronary Intervention, Coronary Artery Bypass Graft, MacNew Scale, Iran

*Date of submission:* 5 Oct 2014, *Date of acceptance:* 4 Apr 2016

#### Introduction

Coronary artery disease (CAD) is the result of the accumulation of atherosclerotic plaques within the walls of the coronary arteries leading to narrowing of the blood vessels, heart failure, angina pectoris, and myocardial infarction (MI). The CAD is the leading and the most common

cause of morbidity and mortality in worldwide.<sup>1-</sup>

<sup>3</sup> It is estimated that low- and middle-income countries contribute to about 80% of cardiovascular disease deaths in world.<sup>4</sup>

Recent data show a high prevalence of CAD and its risk factors such as cigarette smoking, diabetes mellitus, hypertension, dyslipidemia,

1- Health Management and Economic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2- Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Foresterhill, Aberdeen, Scotland

3- Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4- Health Management and Economics Research Center AND School of Health Management and Information Sciences, Tehran University of Medical Sciences, Tehran, Iran

5- Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran

6- Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence to: Razieh Yazdani-Bakhsh, Email: razyzdany@gmail.com

low level of physical activity, and obesity among Iranian population.<sup>5,6</sup>

Although numerous studies have compared the outcomes of coronary revascularization between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery but beyond the survival benefit of CABG and PCI, functional recovery is the expectation of patients who receive these treatments for relief of symptoms. Therefore, an importance of health-related quality of life (HRQOL) in clinical research has been extensively discussed over recent decades and there is an increasing recognition among clinicians and researchers that the impact of chronic illnesses and their treatments must be assessed in terms of their HRQOL in addition to more traditional measures of clinical outcomes—morbidity and mortality.<sup>7,8</sup> The HRQOL has also been used increasingly as a factor in cost effectiveness analysis and health technology assessment that is used to determine the relative value for many of different forms of the treatment.<sup>9</sup> Hence, information on HRQOL of patients in different modes of coronary revascularization and its determinants is so important to defining a comprehensive plan of care. Since there are few studies regarding HRQOL of CAD in different therapeutic interventions in developing countries, therefore the main aim of this study was to comparison of HRQOL of patients who underwent CABG and PCI and to assess its main determinants in the whole sample of Iranian CAD patients.

### Materials and Methods

A follow-up provident study was carried out after 6 and 24 months on patients who underwent coronary revascularization with either PCI or CABG. We identified between 20 March, 2010, and 20 September, 2010, about 389 patients underwent coronary revascularization at Chamran Heart Center of Isfahan, Iran. Before enrollment, the patients received detailed written and verbal information regarding the aims and protocol of the study and signed informed consent. If patients had ability to answer the questions, they filled it personally; otherwise a trained interviewer collected the necessary data through face-to-face

interviews with respondents. The study has been approved by the Ethics Committee of the Isfahan University of Medical Sciences. Patients were excluded if they had prior PCI, CABG or also required valve surgery and passed < 6 months from their treatment. Finally among eligible patients, 109 [PCI (n = 75) and CABG (n = 34)] consented to enter the study. After treatment, 6 and 24 months QOL was evaluated to all participants of both groups.

The HRQOL data were obtained using MacNew Heart Disease HRQOL questionnaire that is a disease specific questionnaire designed to measure HRQOL in patients with cardiac disease, particularly MI and other types of ischemic heart disease.<sup>10</sup> The questionnaire validated and translated to Farsi by Asadi-Lari *et al.*<sup>11</sup> The MacNew consists of 27 questions that inquire about symptoms such as angina/chest pain, shortness of breath, fatigue, dizziness, and aching legs and finally summarized into three main domains, emotional, physical, and social wellbeing. Scoring of the MacNew is straight-forward the maximum possible score in any domain is 7 (high HRQOL) and the minimum is 1 (poor HRQOL). All scales were transformed so that they had a possible range of 0-100, with a higher score indicating a better level of functioning or HRQOL. Socio-demographic, clinical and comorbidity data were extracted from patients' medical records.

The continuous variables were expressed as a mean  $\pm$  standard deviation and categorical variables as absolute numbers and percentages. We studied the association between and within groups in quantitative variables by paired Student's t-test and independent t-test. All statistical tests were two-sided and the significance level was set at 0.05. For QOL scores, distribution used Kolmogorov-Smirnov test. For the test of investigation, the relationship between data and demographics variables were analyzed by chi-square-test. A linear regression model was employed to examine the effect of variables and characters on QOL aspects in CAD patients. We used of Pearson correlation coefficient for study association of HRQOL with characteristics of patients. SPSS software for Windows (version

16.0, SPSS Inc., Chicago, IL, USA) was used to analysis the data.

## Results

From all recruited patients 109 (after 6 months) and 106 persons (after 24 months) completed the questionnaire. One patient in CABG group and two patients in PCI group died during follow-up. Main characteristics of the studied patients are summarized in table 1. The two groups were tested for significant differences regarding socio-demographic and main comorbidity and clinical variables. As seen, the groups can be considered equivalent with no statistically significant differences between them ( $P > 0.050$ ) except in education level ( $P = 0.009$ ). The tests of HRQOL distribution were normal. The mean age of the patients in CABG and PCI group were  $53.2 \pm 5$  and  $51.2 \pm 6.2$  years, respectively, did not show a significant difference ( $P = 0.207$ ). Our results showed that, respectively, in CABG and PCI group (79.4%) and (85.3%) were male, (76.5%) and (50.7%) had < 6 grades education, (79.4%) and (86.7%) were employed, (47.1%) and (54.7%) were smoker, (26%) and (29.3%) had diabetes comorbidity, (32.4%) and (33.3%) had hypertension, (47.1%) and (52.0%) were overweight or obese, (38.2%) and (56.0%) had history of MI and (52.9%) and (53.3%) had hypercholesterolemia.

### Between-group comparison results

Table 2 shows the mean difference scores for total and the three subscales of the MacNew in two groups 6 months and 2 years after revascularization. According to mean difference QOL score in 6 and 24 months after treatment by independent student's test in CABG and PCI were  $8.20 \pm 3.12$  ( $P = 0.010$ ) and  $2.61 \pm 3.28$ , respectively ( $P = 0.428$ ). The overall QOL score in CABG and PCI group in 6 months after treatment were  $45.32 \pm 13.75$  and  $53.52 \pm 15.63$ , respectively ( $P = 0.010$ ). After 2 years these numbers changed to  $51.17 \pm 14.80$  and  $49.55 \pm 16.22$ , respectively, in CABG and PCI group ( $P = 0.428$ ). The highest score of the MacNew subscales was found in the physical ( $46.19 \pm 14.87$ ) and social ( $55.62 \pm 16.75$ ) subscales in CABG and PCI group (after 6

months). However, after 2 years, the best results of the MacNew subscales were related to the emotional subscales and the lowest score was related to physical dimension in both groups. The results showed significant difference in 6 months after treatment (0.01), whereas HRQOL was not a significant difference between two groups (0.428) after 2 years (Table 2).

**Table 1.** Characteristics of patients in coronary artery bypass graft (CABG) (n = 34) and percutaneous coronary intervention (PCI) (n = 75) group

Indicator	CABG n (%)	PCI n (%)	P
Sex			
Male	27 (79.4)	64 (85.3)	0.438
Age			
< 50	8 (23.5)	29 (38.7)	0.123
≥ 50	26 (76.5)	46 (61.3)	
Education			
< 6 grade	26 (76.5)	38 (50.7)	0.009
≥ 6 grade	8 (23.5)	37 (49.3)	
Income			
Low	17 (50.0)	26 (34.7)	0.267
Middle	12 (35.3)	31 (41.3)	
High	5 (14.7)	18 (24.0)	
Employment			
Employed	27 (79.4)	65 (86.7)	0.328
Smoking	16 (47.1)	41 (54.7)	0.461
Diabetes	9 (26.5)	22 (29.3)	0.747
Hypertension	11 (32.4)	25 (33.3)	0.920
BMI			
< 25	18 (52.9)	36 (48.0)	0.626
≥ 25	16 (47.1)	39 (52.0)	
History of MI	13 (38.2)	42 (56.0)	0.086
Hypercholesterolemia	18 (52.9)	40 (53.3)	0.967

Chi-square test; CABG: Coronary artery bypass graft; PCI: Percutaneous coronary intervention; BMI: Body mass index; MI: Myocardial infarction

### Within-group comparison results

Results of within-group by paired Student's t-test showed that in CABG group total MacNew scale were significantly increase ( $P = 0.001$ ) but no significant in [emotional ( $P = 0.122$ ), physical ( $P = 0.026$ ), social ( $P = 0.064$ )]. While significantly decrease (0.016) in PCI group's scores and in subscale except of emotional ( $P = 0.244$ ) difference significant on physical ( $P = 0.007$ ) and social ( $P = 0.025$ ) dimensions were detected (Table 3).

**Table 2.** The mean difference of MacNew Scale scores in coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) group 6 months and 2 years after revascularization (between-group comparison)

MacNew Scale	After 6 months	Mean ± SD	P	After 2 years	Mean ± SD	P
Total score						
CABG	45.32 ± 13.75	-8.20 ± 3.12	0.010	51.17 ± 14.80	2.61 ± 3.28	0.428
PCI	53.52 ± 15.63			49.55 ± 16.22		
Emotional						
CABG	46.15 ± 16.12	-7.60 ± 3.39	0.027	51.80 ± 17.20	0.65 ± 3.71	0.861
PCI	53.75 ± 16.53			51.14 ± 18.12		
Social						
CABG	45.29 ± 13.88	-10.33 ± 3.29	0.002	51.35 ± 15.10	0.47 ± 3.51	0.894
PCI	55.62 ± 16.75			50.88 ± 17.57		
Physical						
CABG	46.19 ± 14.87	-7.79 ± 3.39	0.024	50.39 ± 14.11	3.56 ± 3.32	0.285
PCI	53.46 ± 17.32			46.82 ± 16.72		

Comparison between group in 6 month and after 2 years (independent Student's t-test); CABG: Coronary artery bypass graft; PCI: Percutaneous coronary intervention; SD: Standard deviation

### HRQOL of CAD Patients 6 months after revascularization

The mean total MacNew scale and emotional, social and physical subscale in CAD patients (sum of HRQOL options in both groups) were 50.96 ± 15.48, 51.38 ± 16.71, 52.39 ± 16.55 and 51.55 ± 16.72, respectively. Factors predictive in relation to the QOL were analyzed by linear regression.

Our results indicate that patients with male gender, those who had higher level of education and diabetes comorbidity, employed patients, those who had not hypertension, overweight, hypercholesterolemia and history of MI, those

who were not smoker and patients with higher level of income experienced better HRQOL although these differences were only statistically significant in education, income and body mass index (BMI) variables ( $P < 0.050$ ) (Table 4).

### Correlation

Presents the correlations of HRQOL with characteristics of patients were shown in table 5. The correlations were significant at BMI, education, employee, sex hypertension in total HRQOL of PCI group whiles for dimensions and total HRQOL in CABG group, income and education display significant correlation (Table 5).

**Table 3.** Changes in the MacNew Scale and its subscale's scores in coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) group 2 years after revascularization (within-group comparison)

MacNew Scale	CABG		PCI	
	Mean ± SD	P	Mean ± SD	P
Total score				
After 6	45.32 ± 13.75	0.001	53.52 ± 15.63	0.016
After 24	51.36 ± 14.25		49.94 ± 16.46	
Emotional				
After 6	46.15 ± 16.12	0.122	53.75 ± 16.53	0.244
After 24	51.08 ± 16.94		51.36 ± 18.17	
Social				
After 6	45.29 ± 13.88	0.064	55.62 ± 16.75	0.025
After 24	50.44 ± 14.36		51.27 ± 17.77	
Physical				
After 6	46.19 ± 14.87	0.260	53.46 ± 17.32	0.007
After 24	49.49 ± 13.31		47.48 ± 18.04	

Paired Student's t-test; CABG: Coronary artery bypass graft; PCI: Percutaneous coronary intervention; SD: Standard deviation

**Table 4.** Linear regression analysis of coronary artery disease (CAD) patients 6 months after revascularization according to characteristics (n = 109)

Variable	Mean ± SD	Age	Sex	Education	Income	Employment	Smoking	Hypercholesterolemia	Hypertension	Diabetes	BMI	History of MI
Total MacNew Score	50.96 ± 15.48											
	Standard error	2.319	11.342	2.855	1.850	11.267	2.392	2.241	2.394	2.615	3.142	2.161
	Beta	0.021	-0.200	0.091	0.471	0.189	0.080	0.064	-0.105	0.112	-0.297	-0.011
	P	0.756	0.467	0.070	0.001	0.478	0.307	0.381	0.153	0.145	0.004	0.878
Emotional subscale	51.38 ± 16.71											
	Standard error	2.801	13.697	3.290	2.234	13.606	2.889	2.707	2.891	3.158	3.846	2.609
	Beta	-0.075	-0.258	-0.215	0.262	0.007	0.142	0.058	-0.055	0.096	-0.545	-0.053
	P	0.329	0.401	0.210	0.012	0.981	0.106	0.477	0.499	0.263	0.001	0.499
Social subscale	52.39 ± 16.55											
	Standard error	2.815	13.76	3.306	2.245	13.674	2.904	2.720	2.905	3.173	3.865	2.622
	Beta	0.044	-0.569	0.442	0.256	0.370	0.147	-0.074	-0.077	0.092	-0.354	0.072
	P	0.572	0.070	0.040	0.016	0.222	0.098	0.372	0.353	0.294	0.002	0.367
Physical subscale	51.55 ± 16.72											
	Standard error	2.858	13.975	3.518	2.279	13.883	2.948	2.762	2.949	3.222	3.924	2.662
	Beta	0.355	-0.349	-2.049	2.945	-0.113	1.664	-0.204	-1.694	0.920	-2.406	-0.134
	P	0.723	0.728	0.043	0.004	0.910	0.099	0.839	0.094	0.360	0.002	0.894

SD: Standard deviation; BMI: Body mass index; MI: Myocardial infarction

**Table 5.** Correlation of health-related quality of life (HRQOL) with characters

Variables	PCI				CABG			
	Emotional	Social	Physical	Total	Emotional	Social	Physical	Total
Age	0.026	0.074	0.136	0.059	0.092	0.294	0.274	0.213
Education	-0.092	0.122	0.159	0.265*	0.266	0.426*	0.507**	0.446*
Sex	-0.247	-0.172	-0.064	0.334**	0.172	0.312	0.263	0.229
Employee	-0.151	-0.080	-0.011	0.438**	0.172	0.312	0.263	0.229
Smoking	-0.018	-0.041	0.055	0.100	-0.135	0.113	0.086	-0.003
Hypertension	0.009	-0.107	-0.126	-0.236*	0.175	0.013	-0.052	0.093
Diabetes comorbidity	0.102	0.045	-0.016	-0.088	-0.017	0.113	0.128	0.086
BMI	-0.047	-0.033	-0.033	-0.373**	-0.083	-0.001	-0.062	-0.132
History of MI	-0.094	0.015	-0.003	-0.056	-0.233	-0.192	-0.208	-0.202
Income	0.209	0.177	0.190	0.015	0.374*	0.522**	0.555**	0.495**
Hypercholesterolemia	0.067	-0.021	0.045	0.014	0.052	0.044	-0.045	0.060

Pearson correlation coefficient; \* Correlation is significant at the 0.05 level (two-tailed); \*\* Correlation is significant at the 0.01 level (two-tailed); PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; BMI: Body mass index; MI: Myocardial infarction

## Discussion

In this study after proving similarity of patients in two groups in the aspect of socio-demographic and clinical characteristics, data analysis revealed that those who underwent PCI experienced significantly higher HRQOL in all dimensions of MacNew scale 6 months after revascularization but over 2 years follow-up there was not a significant difference between two groups. This finding is in agreement with results of a study that has been conducted recently by Lopenen et al. to assess HRQOL after CABG and PCI in the management of stable CAD. They found that a 3 years survival was similar in the both groups and the HRQOL improved statistically in both groups until 6 months after treatment but deteriorated toward the end of the follow-up of 36 months. Despite initially more serious pre-operative morbidity, the CABG patients achieved an equal level of HRQOL when compared with PCI patients.<sup>12</sup>

The CAD imposes a high burden on communities in worldwide in terms of premature mortality, adverse effects on QOL and economic impacts on families and health systems.<sup>2,12,13</sup> It is evident that goal for the treatment of patients with the CAD is not just to prolong life but also to provide a better HRQOL. Therefore, the HRQOL has become an important measure of the outcome of care for patients with chronic diseases in the last two decades and it has also been found to be a predictor of health service utilization and mortality.<sup>14,15</sup> Hereupon, information on QOL of CAD patients in different modes of revascularization and its determinant is so important to defining a comprehensive plan of care.

Notwithstanding many studies have demonstrated that CABG and PCI provided a similar degree of protection against death and MI and shown that patients who undergo PCI are much more likely to have recurrent angina and to require repeat procedures<sup>16</sup> but few randomized trials have included HRQOL comparisons after PCI and CABG.

Our results in within-group analysis showed in both groups total MacNew scale and its subscales were changed significantly after 2 years. Norris et al. conducted other study to

compare risk-adjusted HRQOL in 3392 patients with 1 year follow-up. Their results revealed that responders undergoing CABG reported significantly better HRQOL in all but one Seattle Angina Questionnaire dimension compared with who had either a PCI with or without stent.<sup>13</sup> A similar finding has been detected in other study that evaluated change in HRQOL after cardiac rehabilitation among 2441 patients.<sup>17</sup> In general and based on a comprehensive study conducted by Bravata et al.<sup>18</sup> to assess comparative effectiveness of PCI and CABG for CAD-11 randomized trials included in final analysis-they concluded HRQOL scores improved to a significantly greater extent after CABG than after PCI between 6 months and 3 years of follow-up but equalized thereafter.

Our results showed in the whole sample of CAD patients 6 months after revascularization, those who had higher level of income and education and were not either overweight or obese experienced better HRQOL while other covariates were not significantly associated with HRQOL. Several studies have been shown that educational and socioeconomic status are closely associated with the HRQOL.<sup>19,20</sup> Interestingly, age and sex, which are well known as predictors of HRQOL perception,<sup>21,22</sup> were not found to be determinant for HRQOL in our study. In accordance with our results, Durmaz et al.<sup>23</sup> found that sex and age were not important determinant for HRQOL.

Regarding clinical variables, previous MI, diabetes comorbidity, hypertension, and hypercholesterolemia were not found to be an important determinant for HRQOL. Since a number of studies have reported clinical predictors of HRQOL in CAD such as peripheral vascular disease, hypertension, and MI.<sup>21,23,24</sup> It seems the effect of clinical variables on the perception of health status was somewhat unique in this study and merits further investigation.

Since some may argued that generic HRQOL measuring instruments are not able to illustrate impact of different treatment methods and disease's effect on HRQOL's dimension of patients, therefore we used the MacNew Heart Disease HRQOL because it incorporates

domains that address a patient's attitudes toward coronary disease with specific questions regarding disease-specific symptoms and their attitude toward the illness that this is a strength of our study.

However, there are several limitations of our study that need to be considered in interpreting results. However our patients in two groups were similar but it is important to consider the differences among patients carefully when treatment outcomes are analyzed. It is difficult for case-mix adjustments to account adequately for these differences in analyzing patients' outcome in relation to CABG and PCI method. Moreover, since this study was carried out in only one province, our sample may not be representative of whole patients with CAD. Nonetheless, we have noted the paucity of information regarding HRQOL in CAD patients, particularly about two main modes of coronary revascularization in developing countries.

### Conclusion

Our results showed that patients who underwent PCI experienced significantly higher HRQOL in 6 months after revascularization but over 2 years follow-up there was not a significant difference between two groups. Selecting an optimal method of coronary revascularization is a complex clinical decision-making process that needs clinicians incorporate a number of clinical factors, technical considerations, and patient preferences. Therefore in addition to clinical issues, patients' preferences for specific aspects of HRQOL should be considered and tradeoff must be discussed when informing patients about coronary revascularization choices.

### Acknowledgments

The authors would like to thank kindly all participants in the study. This work was supported partially by Tehran University of Medical Sciences, Iran.

### Conflict of Interests

Authors have no conflict of interests.

### References

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001; 104(22): 2746-53.
2. Habib SH, Saha S. Burden of non-communicable disease: Global overview. *Diabetes Metab Syndr* 2008; 4(1): 41-7.
3. Deaton C, Froelicher ES, Wu LH, Ho C, Shishani K, Jaarsma T. The global burden of cardiovascular disease. *J Cardiovasc Nurs* 2011; 26(4 Suppl): S5-14.
4. Morabia A, Abel T. The WHO report "Preventing chronic diseases: a vital investment" and us. *Soz Praventivmed* 2006; 51(2): 74.
5. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. *Arch Iran Med* 2013; 16(3): 138-44.
6. Hadaeigh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. *East Mediterr Health J* 2009; 15(1): 157-66.
7. Ardito SQ, Bestetti RB, Cardinalli-Neto A, Otaviano AP, Nogueira PR. Chronic renal impairment in patients with Chagas cardiomyopathy with chronic systolic heart failure: prevalence and prognostic significance. *Int J Cardiol* 2011; 152(1): 133-4.
8. Joshi VD, Mooppil N, Lim JF. Validation of the kidney disease quality of life-short form: a cross-sectional study of a dialysis-targeted health measure in Singapore. *BMC Nephrol* 2010; 11: 36.
9. Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. *Curr Med Res Opin* 2005; 21(11): 1777-83.
10. Kim C, Bernstein SJ. Quality of life assessment for chronic stable angina. *Expert Rev Pharmacoecon Outcomes Res* 2003; 3(5): 637-50.
11. Asadi-Lari M, Javadi HR, Melville M, Oldridge NB, Gray D. Adaptation of the MacNew quality of life questionnaire after myocardial infarction in an Iranian population. *Health Qual Life Outcomes* 2003; 1: 23.
12. Loponen P, Luther M, Korpilahti K, Wistbacka JO, Huhtala H, Laurikka J, et al. HRQOL after coronary artery bypass grafting and percutaneous coronary intervention for stable angina. *Scand Cardiovasc J* 2009; 43(2): 94-9.
13. Norris CM, Saunders LD, Ghali WA, Brant R, Galbraith PD, Graham M, et al. Health-related quality of life outcomes of patients with coronary artery disease treated with cardiac surgery, percutaneous coronary intervention or medical management. *Can J Cardiol* 2004; 20(12): 1259-66.

14. Dorr DA, Jones SS, Burns L, Donnelly SM, Brunner CP, Wilcox A, et al. Use of health-related, quality-of-life metrics to predict mortality and hospitalizations in community-dwelling seniors. *J Am Geriatr Soc* 2006; 54(4): 667-73.
15. DeSalvo KB, Fan VS, McDonell MB, Fihn SD. Predicting mortality and healthcare utilization with a single question. *Health Serv Res* 2005; 40(4): 1234-46.
16. Naik H, White AJ, Chakravarty T, Forrester J, Fontana G, Kar S, et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. *JACC Cardiovasc Interv* 2009; 2(8): 739-47.
17. Muller-Nordhorn J, Kulig M, Binting S, Voller H, Gohlke H, Linde K, et al. Change in quality of life in the year following cardiac rehabilitation. *Qual Life Res* 2004; 13(2): 399-410.
18. Bravata DM, McDonald KM, Gienger AL, Sundaram V, Perez MV, Varghese R, et al. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease [Internet]. *Journal of General Internal Medicine* 2007.
19. Luttik ML, Jaarsma T, Veeger N, van Veldhuisen DJ. Marital status, quality of life, and clinical outcome in patients with heart failure. *Heart Lung* 2006; 35(1): 3-8.
20. Lukkarinen H, Hentinen M. Assessment of quality of life with the Nottingham Health Profile among patients with coronary heart disease. *J Adv Nurs* 1997; 26(1): 73-84.
21. Duenas M, Ramirez C, Arana R, Failde I. Gender differences and determinants of health related quality of life in coronary patients: a follow-up study. *BMC Cardiovasc Disord* 2011; 11: 24.
22. Unsar S, Sut N, Durna Z. Health-related quality of life in patients with coronary artery disease. *J Cardiovasc Nurs* 2007; 22(6): 501-7.
23. Durmaz T, Ozdemiir O, Ozdemiir BA, Keles T, Bayram NA, Bozkurt E. Factors affecting quality of life in patients with coronary heart disease. *Turkish J Med Sci* 2009; 39(3): 343-51.
24. Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W, Hlatky M, et al. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. *J Am Coll Cardiol* 2003; 41(10): 1732-8.

**How to cite this article:** Yazdani-Bakhsh R, Javanbakht M, Sadeghi M, Mashayekhi A, Ghaderi H, Rabiei K. **Comparison of health-related quality of life after percutaneous coronary intervention and coronary artery bypass surgery.** *ARYA Atheroscler* 2016; 12(3): 124-31.

# Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cardiovascular event in an Iranian cohort study: The Isfahan Cohort Study

Davoud Kazemi-Saleh<sup>(1)</sup>, Pooya Koosha<sup>(2)</sup>, Masoumeh Sadeghi<sup>(3)</sup>, Nizal Sarrafzadegan<sup>(4)</sup>, Reza Karbasi-Afshar<sup>(5)</sup>, Mansoureh Boshtam<sup>(6)</sup>, Shahram Oveis-Gharan<sup>(7)</sup>

## Original Article

### Abstract

**BACKGROUND:** Numerous studies have been conducted on the predictive effects of high-sensitivity C-reactive protein (hs-CRP) on cardiovascular events. Few studies have been conducted to investigate the effects of adiponectin for the prediction of the incident of cardiovascular events in the Middle East area. This study compared the predictive effect of hs-CRP and adiponectin on healthy volunteers for the prediction of cerebrovascular disease (CVD).

**METHODS:** This nested case-control in original Isfahan Cohort Study (ICS) was conducted from 2001 to 2011. Participants were selected from ICS. The case group included participants with CVD while the control group included participants without CVD. The level of hs-CRP and adiponectin was measured in the blood samples collected in the year 2007. Thereafter, the statistical analyses were performed to determine the predictive value of hs-CRP and adiponectin in CVD prediction.

**RESULTS:** The results showed that before the elimination of diabetes effect; there was a significant difference between the two groups, in terms of the mean of adiponectin ( $P = 0.019$ ) and no significant difference was observed in hs-CRP levels ( $P = 0.673$ ). However, after eliminating the factor of diabetes, there was no significant difference between the case and control groups in adiponectin and hs-CRP levels ( $P = 0.184$ ,  $P = 0.946$ ). The results showed that the odds ratio (OR) of the adiponectin level was 0.879 [95% confidence interval (CI): 0.719-1.075,  $P = 0.210$ ] while the OR of hs-CRP was 1.045 (95% CI: 0.922-1.185,  $P = 0.491$ ). Furthermore, it was shown that after adjustment for age, sex, and diabetes; the OR of adiponectin was 0.875 (95% CI: 0.701-1.091,  $P = 0.235$ ) and that of hs-CRP was 1.068 (95% CI: 0.935-1.219,  $P = 0.333$ ).

**CONCLUSION:** The results show that adiponectin and hs-CRP cannot be predictors for cardiovascular events in a healthy population. Risk factors such as diabetes limit the use of adiponectin as a CVD predictor.

**Keywords:** Adiponectin, High-Sensitivity C-Reactive Protein, Cardiovascular Disease

*Date of submission:* 5 Feb 2015, *Date of acceptance:* 11 Apr 2016

### Introduction

Cardiovascular disease (CVD) is the main cause of death worldwide.<sup>1</sup> Furthermore, in Iranian population, CVD is a major cause of morbidity and mortality.<sup>2</sup> The current evidence shows that

fat tissue works not only as a storage source but also as an endocrine tissue.<sup>3,4</sup> Adiponectin is a recently introduced inflammatory cytokine and some studies revealed its important metabolic effects.<sup>5</sup> Few studies have reported on

1- Professor, Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2- Resident, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3- Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4- Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

5- Assistant Professor, Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

6- Research Assistant, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

7- Assistant Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan AND Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Correspondence to: Masoumeh Sadeghi, Email: sadeghimasoumeh@gmail.com

adiponectin's anti-inflammatory and anti-atherogenic effects.<sup>6</sup> Some studies discussed the probable anti-atherogenic role of adiponectin while its real physiologic functions are still unknown.<sup>7-10</sup> On the other hand, high-sensitivity C-reactive protein (hs-CRP) has been proposed as a predictive factor for cardiovascular events.<sup>11</sup>

Adiponectin is a protein secreted by adipocytes, so its serum levels may differ with changes in body weight and visceral fat tissues. Lower levels of adiponectin (< 4 µg/ml) may be correlated with diabetes II, insulin resistance, hypertension (HTN), metabolic syndrome, dyslipidemia, and hyperuricemia. Adiponectin has also been mentioned as an anti-atherosclerotic agent. It has been investigated as a biomarker in association with weight gain disorders in some recent studies.<sup>12</sup>

CRP is an acute phase reactant which is synthesized in the liver by stimulation of cytokine interleukin-6 and is also a factor in atherosclerosis plaque development.<sup>13</sup> Several prospective and case-control studies conducted in the United States have shown that CRP is a risk factor for cardiovascular diseases and hs-CRP is a strong predictive factor of mortality and morbidity in cardiovascular patients.<sup>14-17</sup>

It is proposed that physiologic concentrations of adiponectin will inhibit the production of tumor necrosis factor in macrophages connected to the endothelium and thus, will avoid the expression of molecules such as E-selectin, vascular cell adhesion molecule 1, and intercellular adhesion molecule 1.<sup>18-20</sup> Hotta *et al.*<sup>18</sup> and Kumada *et al.*<sup>21</sup> showed that a reduction in adiponectin levels is associated with increased risk of cardiovascular events and will double the chance of disease independently.<sup>12</sup>

As a result of increasing rate of cardiovascular events in the Middle East, knowing more about predictive factors with higher predictive values and lower costs are essential. The purpose of this study was to explore the association of adiponectin and hs-CRP with the incidence of CVD events in adults who participated in the Isfahan Cohort Study (ICS).

## Materials and Methods

This is a nested case-control study in the ICS conducted from 2001 to 2011. The ICS is a part

of a community trial for prevention and control of CVD, named the Isfahan Healthy Program. In fact, the ICS is a population-based continuing longitudinal study of adults with 35 years or more which are residents in urban and rural places of three countries in central Iran.<sup>22</sup>

In the ICS, initially, the informed written consent is taken and then medical interview and physical examination were performed. After that, information about measurable characteristics of every participants and a fasting blood sample was taken which followed standard protocol and using tuned devices that are previously described.<sup>23</sup> All participants in ICS were followed by phone interview every 2 years using standard questionnaires.

For this nested case-control study, the case groups were selected among participants in ICS who had fatal, non-fatal myocardial infarction (MI) and stroke (ischemic) between September 2007 and September 2013, and before the year 2007, they had none of the diseases mentioned. The criteria for the diagnosis of MI were based on the following criteria which the patient who had two of three following characteristics considered MI: (1) Typical chest pain which prolonged for more 30 minutes, (2) ST-elevation for more than 40.1 mV in two contiguous leads, and (3) cardiac biomarkers increasing. The diagnosis of ischemic stroke was defined as rapid-onset focal neurological deficit which sustained for more than 24 hours.<sup>22</sup> The controls were selected among those without the aforementioned events but were matched with the case group during follow-up (density sampling) to make time for risk to be similar between each pair. For each case, the controls were chosen randomly from those members of the cohort who were at risk at the failure time (event date) of the case and matched in terms of age, sex, and hyperlipidemia (HLP). It is noteworthy that all patients in both groups had no history of vascular events such as MI and stroke at the baseline. Identifying the case and control groups were done using the information in the records. They were contacted according to their information in the documents and people with documented ischemic heart disease and stroke were identified.

Demographic data such as age, sex, marital

status, and cardiovascular risk factors such as diabetes (fasting blood sugar  $\geq 126$ ), HTN (systolic blood pressure  $\geq 140$ , diastolic blood pressure  $\geq 90$ ), smoking, obesity (body mass index  $\geq 30$ ), and HLP (total cholesterol  $\geq 200$ , triglyceride  $\geq 150$ ) were collected from the two groups. Blood samples of participants were collected in 2007 and stored at  $-70\text{ }^{\circ}\text{C}$  in Isfahan Cardiovascular Research Center. Adiponectin and hs-CRP levels were measured using commercial kits (DRG, Germany) of radioimmunoassay (RIA) (human) adiponectin. Ethical approval was obtained from the Ethics Committee of Isfahan Cardiovascular Research Centre, the World Health Organization (WHO) collaborating center.

Numerical values were presented as a mean  $\pm$  standard deviation (SD). Categorical factors were reported as number (percentage). T-test or Mann-Whitney test and Chi-square test were used to compare the case and control groups for quantitative and qualitative factors, respectively. The analysis of covariance was used to compare means of adiponectin or hs-CRP in the case and control groups while statistically controlling for diabetes, age, and sex. The conditional logistic regression was used to estimate the odds ratios (ORs). CVD events were assumed to be dependent on variables and adiponectin and hs-CRP as an independent variable while adjusting for age, sex and diabetes.<sup>2</sup>

The data were analyzed using the software package used for statistical analysis SPSS software (version 15.0, SPSS Inc., Chicago, IL, USA).  $P < 0.050$  were considered as statistically significant.

### Results

In this study, 39 patients with cardiovascular disease (cases) and 41 healthy individuals (controls) were included. From the 80 patients studied, 48 patients were males (60%) and 32 were females (40%). The sex distribution between the case and control groups was not significant.

As shown in table 1, the two groups showed no significant difference in terms of age. The other risk factors were also not significantly different in the case and control groups and only diabetes mellitus (DM) was different between the case and control groups ( $P = 0.007$ ).

After the initial analysis of the results, comparison of adiponectin levels between the two groups showed that there were significant differences between the case and control groups ( $P = 0.019$ ).

However, because the prevalence of diabetes differed significantly between the two groups, the factor of diabetes in the comparison between the two groups was adjusted. The results showed that there was no significant difference between the groups in levels of adiponectin ( $P = 0.184$ ) and hs-CRP ( $P = 0.946$ ). The results are shown in table 2.

**Table 1.** Comparison of demographic and risk factors between the case and control groups

Variable	Case (n = 39)	Control (n = 41)	P
Demographics			
Gender (%)			
Male	22 (56)	26 (63.4)	0.523*
Female	17 (44)	15 (36.6)	
Marital status			
Single	3 (7)	5 (12.0)	0.479*
Married	36 (93)	35 (86.0)	
Risk factors			
DM (%)	21 (53)	10 (24.3)	0.007*
HTN (%)	24 (61)	22 (53.6)	0.476*
HLP (%)	31 (79)	30 (73.1)	0.507*
Smoking (%)	6 (15)	7 (17.0)	0.761*
Triglyceride (mg/dl)	194.84 $\pm$ 110.86	164.56 $\pm$ 126.91	0.260**
BMI	27.42 $\pm$ 4.82	26.83 $\pm$ 3.29	0.523**
FBS (mg/dl)	129.77 $\pm$ 68.47	96.95 $\pm$ 26.94	0.006**
SBP (mmHg)	132.05 $\pm$ 22.16	130.70 $\pm$ 19.15	0.770**
DBP (mmHg)	80.76 $\pm$ 13.51	80.06 $\pm$ 10.14	0.790**
Cholesterol (mg/dl)	217.71 $\pm$ 38.84	214.89 $\pm$ 42.22	0.750**
Age	60.21 $\pm$ 9.64	60.42 $\pm$ 10.65	0.927**

\*Chi-square; \*\* t-test; DM: Diabetes mellitus; HTN: Hypertension; HLP: Hyperlipidemia; BMI: Body mass index; FBS: Fasting blood sugar; SBP: Systolic blood pressure; DBP: Diastolic blood pressure

**Table 2.** Comparison of serum parameters between the two groups, with adjustment for confounding risk factors (sex, diabetes, hypertension)

Variable	Case	Control	P*
Lab tests			
Adiponectin ( $\mu\text{g/ml}$ )	$2.637 \pm 2.375$	$3.303 \pm 2.293$	0.184
Hs-CRP ( $\mu\text{g/ml}$ )	$3.671 \pm 3.821$	$3.128 \pm 3.288$	0.946

\* Analysis of covariance analysis; Hs-CRP: High-sensitivity C-reactive protein

They were also detrimentally associated with adiponectin and hs-CRP on CVD and obtained OR. The results showed that the OR of adiponectin level was 0.879 [95% confidence interval (CI): 0.719-1.075,  $P = 0.210$ ] and OR of hs-CRP was 1.045 (95% CI: 0.922-1.185,  $P = 0.491$ ). Moreover, the results showed that after adjustment for age, sex and diabetes, the OR of adiponectin was 0.875 (95% CI: 0.701-1.091,  $P = 0.235$ ) and that of hs-CRP was 1.068 (95% CI: 0.935-1.219,  $P = 0.333$ ).

## Discussion

In this study, the association of adiponectin and hs-CRP with the incidence of cardiovascular events in adults who participated in the ICS was assessed. No prediction role of adiponectin and hs-CRP in CVD was observed.

Oliveira et al.<sup>24</sup> discussed adiponectin as an independent predictive factor for cardiovascular events. Another study conducted with 48 percutaneous coronary intervention-needed patients with coronary diseases (left anterior descending involvement) and a 66-month period of follow-up revealed that the lower serum levels of adiponectin are associated with future cardiovascular events.<sup>25</sup> Although, adiponectin as an adipocytokine has a considerable role in causing cardiovascular events, its clinical importance is still controversial.

A prospective study including 171 patients with ischemic stroke and 171 matched controls compared the serum levels of adiponectin in days 0, 3, 7 and 90 of the event across groups. Adiponectin serum level was significantly lower in the patients, and this level could predict an atheroemboli stroke (OR: 0.75; 95% CI: 0.58-0.91,  $P = 0.009$ ). Adiponectin serum levels also had a positive correlation with the severity of the neurologic defect. The results of this study also showed that plasma levels of adiponectin may be different in the classification of stroke

subtypes and is able to predict neurological defects and stroke outcome.<sup>26</sup>

Animal studies suggest that reduced adiponectin levels in the acute phase of ischemic stroke are a dynamic process. In a study of 31 patients with the first episode of stroke, at intervals of 24 hours, 2-4 days and 5-10 days after ischemic stroke, plasma adiponectin levels were measured three times. On the basis of their results, adiponectin levels were significantly lower in patients with ischemic stroke when compared with other causes of stroke. This may reflect the effect of adiponectin on the predictive value of the occurrence of ischemia.<sup>27</sup>

However, results of studies on the predictive effects of adiponectin on cardiovascular events are conflicting in some cases. In a prospective meta-analysis performed in Europe, the predictive value of adiponectin for cardiovascular events was studied. The relative risk of stroke in adiponectin levels higher than 5  $\mu\text{g/ml}$  was about 1.10 with 95% CI: 0.89-1.37. The patients with higher levels of adiponectin have higher levels of high-density lipoprotein cholesterol and lower triglycerides and CRP.<sup>28</sup> The difference between the present study and studies in America can be attributed to differences in resource classification and naming of different kinds of stroke among various European and American resources.

The mechanism of action of adiponectin in predicting cardiovascular events remains unclear, and several hypotheses have been proposed. For example, adiponectin as an insulin sensitizing hormone was introduced with the assumption that the plasma adiponectin levels in metabolic disorders such as DM Type 2 is reduced and shows the relationship between adiponectin levels, increased risk of cardiovascular events and related deaths.<sup>29</sup>

Results of a cohort study on 4571 at risk African-Americans revealed that adiponectin is

more associated with stroke in females. This study showed that the mechanism of prediction of adiponectin is still unclear but hypotheses have been proposed that the production of this substance is in response to vascular inflammation and deals with atherosclerosis.<sup>30</sup>

Several large prospective epidemiological studies showed that hs-CRP is a strong predictor of cardiovascular events such as MI and stroke.<sup>13</sup> In a cohort study which was conducted with 1086 apparently healthy middle-aged men, participants in the quartile with the highest CRP values had 3 and 2 times the risk of MI and ischemic stroke, respectively, in contrast to subjects with the lowest CRP.<sup>31</sup>

The results of this study show that adiponectin and hs-CRP cannot be predictors for cardiovascular events in a healthy population. The difference between these results and the results of other studies could be because of diabetes which is a confounding factor.

This study had some limitations which could affect the results. One of the restrictions was the small sample size which had impact on the results. Another limitation of this study was the presence of confounding variables such as DM in both groups.

However, as mentioned, the use of adiponectin as an independent predictor of cardiovascular events continues to be associated with controversy. On the other hand, there is no population-based study to evaluate this effect. Future studies to examine the predictive effects of adiponectin as compared to other biomarkers with larger sample sizes are recommended.

### Conclusion

The results of this study show that adiponectin and hs-CRP cannot be predictors for cardiovascular events in a healthy population. Risk factors such as diabetes, limit the use of adiponectin as a CVD predictor. Further studies with larger sample size should be conducted to determine the predictive role of adiponectin and hs-CRP in CVD.

### Acknowledgments

We are thankful to the team of the ICRC, Isfahan Provincial Health Center, Najafabad

Health Office and the Arak University of Medical Sciences, Iran.

### Conflict of Interests

Authors have no conflict of interests.

### References

1. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. *Eur Heart J* 2010; 31(6): 642-8.
2. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. *Arch Iran Med* 2013; 16(3): 138-44.
3. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. *Intern Med* 1999; 38(2): 202-6.
4. Talaei M, Sadeghi M, Marshall T, Thomas GN, Kabiri P, Hoseini S, et al. Impact of metabolic syndrome on ischemic heart disease - a prospective cohort study in an Iranian adult population: Isfahan Cohort Study. *Nutr Metab Cardiovasc Dis* 2012; 22(5): 434-41.
5. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. *Curr Opin Lipidol* 2002; 13(1): 51-9.
6. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. *Lancet* 2002; 360(9326): 57-8.
7. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem* 1995; 270(45): 26746-9.
8. Kishore U, Reid KB. C1q: structure, function, and receptors. *Immunopharmacology* 2000; 49(1-2): 159-70.
9. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem* 1996; 271(18): 10697-703.
10. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab* 2001; 86(5): 1930-5.
11. Khaledi Y, Aghababaei E, Sadeghi M, Hashemi M, Sanei H. Evaluation of heart rate reserve and high-sensitivity C-reactive protein in individuals with and without metabolic syndrome in Isfahan, Iran. *ARYA Atheroscler* 2012; 8(2): 70-5.

12. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. *Best Pract Res Clin Endocrinol Metab* 2014; 28(1): 119-30.
13. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. *J Am Osteopath Assoc* 2005; 105(9): 409-16.
14. Giffen PS, Turton J, Andrews CM, Barrett P, Clarke CJ, Fung KW, et al. Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein. *Arch Toxicol* 2003; 77(7): 392-402.
15. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. *Arterioscler Thromb Vasc Biol* 2003; 23(7): 1255-61.
16. Choobineh S, Dabidy Roshan V, Gaieni AA. Effect of the continues and intermittence aerobic training on high - sensitive c-reactive protein in rats. *Journal of Movement Science and Sport* 2007; 5(9): 1-14. [In Persian].
17. Baptista S, Piloto N, Reis F, Teixeira-de-Lemos E, Garrido AP, Dias A, et al. Treadmill running and swimming imposes distinct cardiovascular physiological adaptations in the rat: focus on serotonergic and sympathetic nervous systems modulation. *Acta Physiol Hung* 2008; 95(4): 365-81.
18. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 2000; 20(6): 1595-9.
19. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2002; 290(3): 1084-9.
20. Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. *Horm Metab Res* 2000; 32(11-12): 548-54.
21. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. *Arterioscler Thromb Vasc Biol* 2003; 23(1): 85-9.
22. Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, et al. The Isfahan cohort study: rationale, methods and main findings. *J Hum Hypertens* 2011; 25(9): 545-53.
23. Sadeghi M, Talaei M, Zand I, Oveisgharan S, Iranipour R, Esteki GF, et al. Heart rate and cardiovascular events: a nested case-control in Isfahan Cohort Study. *Arch Iran Med* 2014; 17(9): 633-7.
24. Oliveira GB, Franca JI, Piegas LS. Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. *Arq Bras Cardiol* 2013; 101(5): 399-409.
25. Kawagoe J, Ishikawa T, Iwakiri H, Date H, Imamura T, Kitamura K. Association between adiponectin production in coronary circulation and future cardiovascular events in patients with coronary artery disease. *Int Heart J* 2014; 55(3): 239-43.
26. Kuwashiro T, Ago T, Kamouchi M, Matsuo R, Hata J, Kuroda J, et al. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke-Research for Biomarkers in Ischemic Stroke (REBIOS). *Metabolism* 2014; 63(9): 1093-103.
27. Pera J, Dziedzic T, Szczudlik A, Slowik A. Temporal changes of adiponectin plasma levels in patients with acute ischemic stroke. *Neurol Res* 2013; 35(9): 988-91.
28. Arregui M, Buijsse B, Fritsche A, di Giuseppe R, Schulze MB, Westphal S, et al. Adiponectin and risk of stroke: prospective study and meta-analysis. *Stroke* 2014; 45(1): 10-7.
29. Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, et al. Adiponectin, type 2 diabetes and cardiovascular risk. *Eur J Prev Cardiol* 2015; 22(3): 276-83.
30. Bidulescu A, Liu J, Chen Z, Hickson DA, Musani SK, Samdarshi TE, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in african americans: the jackson heart study. *Front Public Health* 2013; 1: 16.
31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997; 336(14): 973-9.

**How to cite this article:** Kazemi-Saleh D, Koosha P, Sadeghi M, Sarrafzadegan N, Karbasi-Afshar R, Boshtam M, et al. **Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cerebrovascular event in an Iranian cohort study: The Isfahan Cohort Study.** *ARYA Atheroscler* 2016; 12(3):132-7.

# What is role of sex and age differences in marital conflict and stress of patients under Cardiac Rehabilitation Program?

Saeid Komasi<sup>(1)</sup>, Mozhgan Saeidi<sup>(1)</sup>

## Original Article

### Abstract

**BACKGROUND:** To investigate the role of sex and age differences in marital conflict and stress of patients who were under cardiac rehabilitation (CR) program.

**METHODS:** The data of this cross-sectional study were collected from the database of the CR Department of Imam Ali Hospital, Kermanshah, Iran. The demographics and medical data of 683 persons were collected from January 2003 and January 2010 using medical records, the Beck Anxiety Inventory, the Beck Depression Inventory, the Hudson's Index of Marital Stress, and the Structured Clinical Interview for axis I disorders. Data were analyzed through Analysis of Covariance and Bonferroni test.

**RESULTS:** About 74.8% of the subjects were male. After adjustment for age, educational level, anxiety, and depression-the findings showed that women in CR program had a higher level of marital stress compared to men ( $54.75 \pm 2.52$  vs.  $49.30 \pm 0.89$ ;  $P = 0.042$ ). Furthermore, it was revealed that women who aged 56-65 years and more experienced higher level of marital stress compared to younger patients ( $P < 0.050$ ); however, no significant difference was observed between different age groups in male patients ( $P > 0.050$ ).

**CONCLUSION:** Marital conflict and stress threaten healthiness of women who aged 56-65 years more prominently than does in males or younger patients. Regarding the effect of marital stress on recurrence of the disease and cardiac-related morbidity and mortality in women, providing effective education and interventions to this group of patients, especially older women and even their spouses could be one of the useful objectives of CR programs.

**Keywords:** Marital Conflict, Psychologic Stress, Sex Differences, Rehabilitation, Cardiac Disease

*Date of submission:* 27 Aug 2015, *Date of acceptance:* 27 Feb 2016

### Introduction

The protective and supportive effects of marriage on healthiness and well-being, in general, population have been demonstrated. It is stated that married individuals have better physical and psychological healthiness than single ones.<sup>1</sup> In patients with cardiovascular diseases (CVDs), as a subset of clinically encountered patients, the role of marriage and being married in the development of the disease and its outcomes has gained attention of the researchers in recent years.<sup>2,3</sup> Recent findings show that there is relationship between marital state and CVDs morbidity and mortality. The likelihood of premature death in single men and divorced women is significantly higher compared to other groups.<sup>4</sup> Furthermore, among

married patients in age group of 45-64 years face premature death less likely in comparison to other groups.<sup>5</sup>

Even though these researches have indicated the positive role of being married on disease, it seems that the state of being married itself may have challenges which have not been investigated thoroughly in cardiac patients. One of these challenges is an inappropriate interaction between couples and marital stress. It has been stated that marital stress as a chronic between person stress decreases the immune function of the body, in particular, in older people. Marital stress, not only increases the risk of health problems such as CVDs,<sup>6</sup> but also challenges health behaviors of patients such as nutrition management.<sup>7</sup> Although the

1- Cardiac Rehabilitation Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran  
Correspondence to: Mozhgan Saeidi, Email: m\_saeidi20@yahoo.com

mechanisms through which marital conflicts affect the healthiness of people,<sup>8</sup> it is evident that negative marital interactions are related to some cardiac reaction indices such as heart rate and systolic blood pressure in both males and females.<sup>9</sup> Marital stress not only increases the recurrence risk of cardiac events into 3-fold in a 5-year period<sup>10</sup> but also independently aggravates depression, anxiety, anger, and hostility in cardiac rehabilitation (CR) patients.<sup>11,12</sup> Marital stress also negatively affects the social relations of women.<sup>13</sup> It also predicts the risk of longer hospitalization after cardiac surgery in women<sup>14</sup> and in men.<sup>15</sup> In addition, appropriate quality of marital relationship especially in female patients with cardiac diseases inhibits systolic hypertension<sup>16</sup> and significantly predicts 4 to 8-year survival.<sup>17,18</sup>

Despite the aforementioned evidence, it is not yet clear exactly that which age or gender groups are affected more by marital stress. As negative aspects of marital relationship affect more significantly physiologic functions of women compared to men,<sup>19</sup> and survival of patients older than 64 years is at higher risk,<sup>5</sup> access to a response to this question is equivocal. Furthermore, designing of appropriate therapeutic procedures requires knowledge about the effect of sex and age on marital stress. Along with gender, age as one of the most important biomarkers among non-specific parameters of cardiac diseases has the highest effect on the disease evolution<sup>20</sup> and increasing age is associated with the risk of development and establishment of CVDs.<sup>21</sup> This issue shows the necessity of evaluation of marital stress in patients in different age groups. Therefore, here two questions arise and the current study was carried out with the purpose of answering to these two questions. The first question is that whether marital stress is higher in female or male patients in CR program? The second question is that which age group experiences the greatest level of marital stress?

## Materials and Methods

In this cross-sectional study, the data were collected through the CR Department of Imam-Ali Hospital in Kermanshah, Iran. Kermanshah

is located 525 km (326 miles) from Tehran in the western part of Iran. According to the 2011 census, its population is 851,405. People mostly speak Southern Kurdish and Persian. The city has a moderate and mountainous climate. Kermanshah is one of the western agricultural core of Iran that produces grain, rice, vegetable, fruits, and oilseeds; however, Kermanshah is emerging as a fairly important industrial city. Imam-Ali Hospital is a state specialized hospital for cardiology in Kermanshah, and the patients residing in Western Iran, in general, visit this hospital. The hospital includes intensive care unit and critical care unit Parts, Cardiac Surgery Department, Emergency Department, CR Unit, and Heart Research Center. Moreover, the governmental hospital has 214 beds. The database of this hospital is consists of data about different types of heart diseases especially cardiac surgery that has been enrolled in CR programs after the cardiac event had occurred. The demographic and medical data of the patients including the comorbidities, psychological health, and the early risk factors are registered in the database. The registration checklists are provided by heart health professionals and specialists under the supervision of Kermanshah University of Medical Sciences (KUMSs). The control center of the KUMS confirms the accuracy of the collected data 2 times in the year. Moreover, to evaluate the psychological state of the cardiac patients including anxiety, depression, and marital stress, standard tools such as the Beck inventories and structured clinical interview (SCID-I) for comorbidities are used in the start of CR in this center. In addition, the self-reported checklists for the illiterate patients were read by the psychologist of the ward and then the answers were registered.

1. Age between 30 and 85 years
2. Being married
3. Lack of substance abuse currently
4. The absence of stabilized psychosis.

We recognized 725 patients under CR enrolled in a 7-year period between January 2003 and January 2010. 22 patients were excluded due to the lack of inclusion criteria. Then, the data of other patients were used for the analysis. However, information of some of them was

confronted with missing data in some items which caused the SPSS software (version 20, SPSS Inc., Chicago, IL, USA) to exclude 20 patients. Thus, the sample size ultimately was declined to 683 persons. We did not perform sampling for selection of participants, but all patients in the mentioned period were enrolled - with the exception of patients without inclusion criteria. Given that there are 8 cells (four age groups  $\times$  two genders  $\times$  single dependent variable = 8) and it is recommended that would have existed in each cell 20 people,<sup>22</sup> as the result seems to be enough sample size 160 people. Thus, our sample size ( $n = 683$ ) is appropriate. Furthermore, due to ethical considerations and after approval of the Ethics Committee of KUMS in January 2015, the patients data were used as confidential and anonymous to protect their privacy.

SCID-I assesses the axis I psychiatric disorders. This instrument is consists of 6 parts for assessments of diagnostic criteria of the 38 disorders such as anxiety and mood disorders and psychosis. The SCID-I done usually in one session and it takes between 45 and 90 minutes.<sup>23</sup> The reliability and validity of the tool for various disorders on axis I is appropriate. The Kappa values of the axis I disorders varied from 0.61 to 0.83, with a mean Kappa of 0.71 (0.60 for agoraphobia to 0.83 for specific and social phobia). Furthermore, the study results showed good inter-rater agreement of the axis I disorders.<sup>24</sup> The Kappa values of Persian version for various disorders are appropriate (0.60 and higher).<sup>25</sup>

- The Beck Anxiety Inventory is consists of 21 items, three scores awarded to each question, and its total score is calculated from 0 to 63. If the score is between 0 and 7, there is no anxiety; if the score is from 8 to 15, there is a mild anxiety; and if the score is from 16 to 25, the patient has moderate anxiety and ultimately; if the patient scores from 26 to 63, the patient suffers from severe anxiety. Cronbach's alpha of the inventory is 0.92, the credential using retest method with 1 week interval is 0.75, and the consistency of the items ranges from 0.30 to 0.76. The content validity revealed that it is suitable to measuring the intensity of anxiety.<sup>26</sup> In Iran, Kaviani and Mousavi were reported the inventory Cronbach's alpha 0.92 and

they found that its validity and reliability is appropriate ( $P < 0.001$ ).<sup>27</sup>

- The Beck Depression Inventory is a 21 items exam of 3 scores for each item. The score of this exam is varied from 0 to 63. Interpreting the results is determined as follows: 0-4 means depression denial; 5-9 equals to very mild depression; 10-18 means the patient has mild to moderate depression; if the patient scores from 19 to 29, it shows moderate to severe depression and the score more than 30 shows that the patients suffer from severe depression. Beck et al. discovered the retest reliability index in 1 week interval as 0.93.<sup>28</sup> Based on the results of a study in Iran, the inventory validity (convergent validity with general health questionnaire-28;  $r = 0.80$ ) and reliability (Cronbach's alpha 0.92) is appropriate.<sup>29</sup>

- Hudson's index of marital stress is a 25 item scale that evaluates the severity of the marital conflict. 13 items of the scale are scored directly and 12 items are scored in reverse. Answers are graded based on the Likert 5-point (rarely to most of the time). The positively worded items were scored in the reverse such that 1 was rescored as 5, 2 as 4, 3 remained as 3, 4 as 2 and 5 as 1. The positively worded items were 1, 3, 5, 8, 9, 11, 13, 16, 17, 19, 20, 21, 23. After this, all the scores were summed up. Score higher than 30 means a considerable marital conflict. However, scores higher than 70 means strong and stable marital conflict. Cronbach's alpha of the scale items is 0.96 which it is indicator from suitable reliability.<sup>30</sup> Based on the results of Sanaei in Iran, the scale validity (content validity with enrich marital satisfaction scale;  $r = 0.86$ ) is appropriate.<sup>31</sup>

We used percentage for report of nominal variables including baseline demographics and risk factors history. Then, these variables were compared between female and male using the chi-squared test. Mean and standard deviation (SD) used for continuous quantitative variables and independent t-test were used for comparison of mean scores of the baseline continuous variables including age, anxiety, and depression. Data normality and outliers were studied with used Kolmogorov-Smirnov test. In addition, preliminary checks were conducted to ensure that there was no violation of the other

assumptions of linearity and homogeneity of variances.<sup>22</sup> Then, the Analysis of Covariance (ANCOVA) and the Bonferroni test was used for comparison of marital stress among the sex and age groups. Applying the covariance analysis using the SPSS software for Windows (version 21.0, SPSS Inc., Chicago, IL, USA) software program, the effect of age, education level, anxiety, and depression in the sex groups was controlled. However, merely the effect of education level, anxiety, and depression was controlled to examine age groups. In the ANCOVA analysis was reported a mean and standard error (SE). The  $P < 0.050$  concerned as significant level.

## Results

Of the total 683 patients, 511 (74.8%) were male.

The age ranges of female and male were 32-82 and 35-82 years, respectively. The total mean  $\pm$  SD of marital stress was  $50.77 \pm 19.66$ . The baseline demographic and clinical variables of the participants are shown in table 1. The table results show significance different between female and male in term of education level, occupation, anxiety, and depression ( $P < 0.001$ ). In addition, non-adjusted and adjusted means  $\pm$  SE of marital stress of the sex groups are shown in table 2. It was revealed that marital stress is significantly higher among female compared to male, both before adjustment for age, education level, anxiety, and depression ( $57.53 \pm 6.05$  vs.  $48.49 \pm 2.96$ ;  $P < 0.001$ ) and after it ( $54.75 \pm 2.52$  vs.  $49.30 \pm 0.89$ ;  $P = 0.042$ ).

**Table 1.** Baseline demographic and clinical characteristics in the cardiac rehabilitation (CR) female and male

Characteristic	Total (n = 683)	Female (n = 172)	Male (n = 511)	P <sup>**,***</sup>
Demographic characteristics				
Education degree (%)				
Illiterate	36.6	64.5	27.2	$< 0.001^*$
Less than diploma	33.8	24.4	37.0	
Diploma	16.7	6.4	20.2	
Academic	12.9	4.7	15.6	
Occupation (%)				
Market	40.4	0.6	53.8	$< 0.001^*$
Clerk	10.7	1.7	13.7	
Retired	25.5	4.7	32.5	
Housewife	23.4	93.0	0.0	
Clinical characteristics				
Index procedure (%)				
CABG	96.9	96.3	98.4	0.194
VHD	1.1	1.3	0.1	
PCI	2.0	2.0	1.5	
Cardiac risk factors (%)				
Diabetes	37.6	34.8	37.9	0.645
Hypertension	30.7	34.8	30.2	0.475
Hyperlipidemia	57.7	56.1	57.9	0.780
Age (mean $\pm$ SD)	$57.66 \pm 9.21$	$56.97 \pm 8.43$	$57.89 \pm 9.46$	0.2610
Anxiety (mean $\pm$ SD)	$30.06 \pm 11.85$	$36.87 \pm 10.76$	$27.77 \pm 11.31$	$< 0.001^*$
Depression (mean $\pm$ SD)	$17.18 \pm 3.40$	$18.51 \pm 3.12$	$16.65 \pm 3.36$	$< 0.001^*$

Significant difference between female and male for each characteristic \*  $P < 0.001$ ; \*\* Chi-square test performed for nominal and categorical variables; \*\*\* t-test performed for continuous variables; CABG: Coronary artery bypass graft surgery; VHD: Valvular heart disease; PCI: Percutaneous coronary intervention; SD: Standard deviation

**Table 2.** The compare of the marital stress mean between female and male before and after adjustment

Characteristics	Marital stress (mean ± SE) (Non-adjusted)	P	Marital stress (mean ± SE) (Adjusted)	P
Sex				
Female	57.53 ± 6.05	0.001*	54.75 ± 2.52	0.042**
Male	48.49 ± 2.96		49.30 ± 0.89	

Significant difference between female and male for each characteristic; \* P < 0.010; \*\* P < 0.050; SE: Standard error

Table 3 presents the patients' marital stress in different age groups in either gender. The results of table show there is not different between non-adjusted means ± SE of female and male (P = 0.773). In addition, after adjustment for educational level, anxiety, and depression no significant difference was observed regarding marital stress between different age groups in male (P = 0.636). However, significant differences were observed in term of marital stress adjusted mean between different age groups in female (P < 0.001). The results of Bonferroni post-hoc test to find differences in marital stress between different age groups in either gender are presented in table 4. After adjustment for education level, anxiety, and depression, the results of the table show that female who aged 56-65 years had significantly higher level of marital stress compared to younger age groups including ≤ 45 years (76.40 ± 5.90 vs. 45.72 ± 7.69; P = 0.013) and 46-55 years (76.40 ± 5.90 vs. 48.77 ± 4.84; P = 0.002). Furthermore, it is obvious that no significant difference was seen between patients > 65 years with other age groups (P > 0.050).

## Discussion

The study was done with the objective of finding difference in marital stress level between genders and also between different age groups of patients who were receiving CR program. The results showed that women experienced higher levels of marital stress compared to men. Plus, age did not have a role in marital stress among men. However, women who aged 56-65 years experienced higher level of marital stress compared to their younger counterparts. In justification of the observed results, it could be stated that women generally are more vulnerable to mental disorders including depression, stress, and anxiety.<sup>32-34</sup> Therefore, it can be expected that marital stress, as one of the items of general chronic stress, to be more severe in women. In support of this finding, the results of a study in 2014 showed that women were more likely to relate their cardiac condition to psychological risk factors, especially stress.<sup>35</sup> As there is relationship between perceived and real risk factors,<sup>36</sup> higher rate of stress reported by women seems natural.

**Table 3.** The compare of the marital stress in different age groups of female and male

Characteristics	Marital stress (mean ± SE) (Non-adjusted)	P	Marital stress (mean ± SE) (Adjusted)	P
Female				
Age (year)		0.102		0.001*
≤ 45 (n = 14)	44.93 ± 11.59		45.72 ± 7.69	
46-55 (n = 56)	55.27 ± 6.05		48.77 ± 4.84	
56-65 (n = 75)	60.61 ± 4.96		76.40 ± 5.90	
> 65 (n = 27)	60.22 ± 6.25		48.72 ± 10.64	
Male				
Age (year)		0.773		0.636
≤ 45 (n = 48)	49.94 ± 4.63		51.78 ± 4.61	
46-55 (n = 161)	48.14 ± 2.82		47.29 ± 1.35	
56-65 (n = 194)	49.10 ± 2.58		48.85 ± 1.37	
> 65 (n = 108)	47.28 ± 3.10		50.05 ± 2.73	

Significant difference between patients for each characteristic; \* P < 0.010; SE: Standard error

**Table 4.** The multi-compare of the marital stress in different age groups before and after adjustment

Group (I)	Group (J)	Mean difference (SE) (Non-adjusted)	P	Mean difference (SE) (Adjusted)	P
Female					
≤ 45	46-55	-10.339 (6.918)	0.823	-3.048 (9.199)	0.999
	56-65	-15.685 (6.741)	0.131	-30.677 (9.871)	0.013*
	> 65	-15.294 (7.625)	0.280	-2.993 (13.139)	0.999
46-55	56-65	-5.345 (4.089)	0.999	-27.629 (7.544)	0.002**
	> 65	-4.954 (5.425)	0.999	0.055 (11.695)	0.999
56-65	> 65	0.391 (5.196)	0.999	27.684 (12.152)	0.144
Male					
≤ 45	46-55	1.801 (2.916)	0.999	4.492 (4.795)	0.999
	56-65	0.834 (2.858)	0.999	2.927 (4.809)	0.999
	> 65	2.660 (3.076)	0.990	1.728 (5.374)	0.999
46-55	56-65	-0.966 (1.890)	0.999	-1.565 (1.918)	0.999
	> 65	0.859 (2.205)	0.999	-2.764 (3.048)	0.999
56-65	> 65	1.825 (2.129)	0.999	-1.199 (3.046)	0.999

Significant difference between patients for each characteristic; \* P < 0.050; \*\* P < 0.010; SE: Standard error

Women are more sensitive to familial stress than men and marital arguments affect their psychological and physiologic health more prominently.<sup>11</sup> They usually spend more time about thinking of marital relationship especially its negative aspects.<sup>14</sup> The rate of expressing anger of marital conflicts is fewer in women. This per se increases the risk of death from cardiac events four times.<sup>37</sup> In women, the quality of the marital relationship is generally affected by the perceived quality of the support by spouse<sup>14</sup> and if women perceive their spouse support more positively there will be less marital stress and better survival.<sup>18</sup> Therefore, it is obvious that gender is a factor that affects more negative perception of marital interactions in women. Due to stronger emotional responses in women, they report higher level of marital stress than men do.

Regarding the effect of age on marital stress, compatible with our results, Zare et al. reported that getting older and longer marriage duration is associated with decreased marital satisfaction in women.<sup>38</sup> Older women as a result of longer duration of their marriage and facing various difficulties throughout these years such as economic issues and problems with children<sup>39</sup> have spent more years with marital conflicts and possible disputes and since Iranian culture has a negative view toward divorce, social coercion to continue the marriage is probably followed by chronic marital stress.

Another justification is the educational level of these patients. Older patients have lower educational level compared to younger women and this state can lead to disagreement between couples and marital conflict.<sup>38</sup> In addition, since these women are illiterate or have a low level of education and have no job, they usually spend more time inside the household and spend less time in outdoor and leisure activities. This state leads to the feeling that home environment is repetitive in days after days, and therefore, women may feel pressure and inability to change the environment. Finally, older women have more physical problems and more limited range of motion which prohibit them from doing activities such as daily walking. Therefore, staying at home leads to nervousness and more marital disputes.

Overall, although CVD is a widespread problem throughout the world, marriage and marital relationship is primarily a cross-cultural issue. Our study participants were mostly Kurdish language that may have certain marital problems. Thus, the study results can help to increase the knowledge of health professionals both about this psychological risk factor and sex and age groups at risk and vulnerable.

Our study has several strengths and limitations. First, marital stress is one of the factors that has received less attention in previous studies. Other strength is the study of one of the aspects of general stress separately.

Using data from a large sample is other advantage our study. Conversely, one of the limitations of our study was that the data were collected from only one hospital. Therefore, caution is required in the generalizing results. The other limitation was lower number of female patients in the research. Therefore, it is recommended to survey more samples throughout the Iran and study more women in the upcoming studies. A third of our limitation was the retrospective nature of some of the collected data. In addition, there was no possibility to control for all confounding variables.

### Conclusion

Marital stress threatens healthiness of women who aged 56-65 years more prominently than does in males or younger patients. Regarding the effect of marital stress on recurrence of the disease and cardiac-related morbidity and mortality in women, providing effective education and interventions to this group of patients, especially older women and even their spouses could be one of the useful objectives of CR programs.

### Acknowledgments

It is hereby deemed necessary to thank and appreciate the staff of the CR Department of the Imam Ali Hospital (KUMSs) for their cooperation in providing data.

### Conflict of Interests

Authors have no conflict of interests.

### References

1. Wright JD. International encyclopedia of the social & behavioral sciences. In: Carr D, Pudrovska T, Editors. Marital quality and health. 2<sup>nd</sup> ed. Philadelphia, PA: Elsevier; 2015.
2. Barbash IM, Gaglia MA, Torguson R, Minha S, Satler LF, Pichard AD, et al. Effect of marital status on the outcome of patients undergoing elective or urgent coronary revascularization. *Am Heart J* 2013; 166(4): 729-36.
3. Consuegra-Sanchez L, Melgarejo-Moreno A, Jaulent-Huertas L, Diaz-Pastor A, Escudero-Garcia G, Vicente-Gilabert M, et al. Unraveling the relation between marital status and prognosis among myocardial infarction survivors: Impact of being widowed on mortality. *Int J Cardiol* 2015; 185: 141-3.
4. Molloy GJ, Stamatakis E, Randall G, Hamer M. Marital status, gender and cardiovascular mortality: behavioural, psychological distress and metabolic explanations. *Soc Sci Med* 2009; 69(2): 223-8.
5. Johnson NJ, Backlund E, Sorlie PD, Loveless CA. Marital status and mortality: the national longitudinal mortality study. *Ann Epidemiol* 2000; 10(4): 224-38.
6. Gallo LC, Troxel WM, Kuller LH, Sutton-Tyrrell K, Edmundowicz D, Matthews KA. Marital status, marital quality, and atherosclerotic burden in postmenopausal women. *Psychosom Med* 2003; 65(6): 952-62.
7. Jaremka LM, Glaser R, Malarkey WB, Kiecolt-Glaser JK. Marital distress prospectively predicts poorer cellular immune function. *Psychoneuroendocrinology* 2013; 38(11): 2713-9.
8. Whitson SA, El-Sheikh M. Marital conflict and health: Processes and protective factors. *Aggress Violent Behav* 2003; 8: 283-312.
9. Nealey-Moore JB, Smith TW, Uchino BN, Hawkins MW, Olson-Cerny C. Cardiovascular reactivity during positive and negative marital interactions. *J Behav Med* 2007; 30(6): 505-19.
10. Orth-Gomer K, Wamala SP, Horsten M, Schenck-Gustafsson K, Schneiderman N, Mittleman MA. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. *JAMA* 2000; 284(23): 3008-14.
11. Balog P, Janszky I, Leineweber C, Blom M, Wamala SP, Orth-Gomer K. Depressive symptoms in relation to marital and work stress in women with and without coronary heart disease. The Stockholm Female Coronary Risk Study. *J Psychosom Res* 2003; 54(2): 113-9.
12. Saeedi M, Komasi S, Heydarpour B, Soroush A. The role of marital stress in intensifying depression symptoms, anxiety, and anger: a comparison of two groups of cardiac rehabilitation patients. *J Clinical Care* 2015; 2(4): 32-9.
13. Blom M, Janszky I, Balog P, Orth-Gomer K, Wamala SP. Social relations in women with coronary heart disease: the effects of work and marital stress. *J Cardiovasc Risk* 2003; 10(3): 201-6.
14. Kulik JA, Mahler HI. Marital quality predicts hospital stay following coronary artery bypass surgery for women but not men. *Soc Sci Med* 2006; 63(8): 2031-40.
15. Kulik JA, Mahler HI. Social support and recovery from surgery. *Health Psychol* 1989; 8(2): 221-38.
16. Tobe SW, Kiss A, Sainsbury S, Jesin M, Geerts R, Baker B. The impact of job strain and marital cohesion on ambulatory blood pressure during 1 year: the double exposure study. *Am J Hypertens* 2007; 20(2): 148-53.

17. Coyne JC, Rohrbaugh MJ, Shoham V, Sonnega JS, Nicklas JM, Cranford JA. Prognostic importance of marital quality for survival of congestive heart failure. *Am J Cardiol* 2001; 88(5): 526-9.
18. Rohrbaugh MJ, Shoham V, Coyne JC. Effect of marital quality on eight-year survival of patients with heart failure. *Am J Cardiol* 2006; 98(8): 1069-72.
19. Kiecolt-Glaser JK, Newton TL. Marriage and health: his and hers. *Psychol Bull* 2001; 127(4): 472-503.
20. Blokh D, Stambler I. Information theoretical analysis of aging as a risk factor for heart disease. *Aging Dis* 2015; 6(3): 196-207.
21. Tabei SM, Senemar S, Saffari B, Ahmadi Z, Haqqarast S. Non-modifiable Factors of Coronary Artery Stenosis in Late Onset Patients with Coronary Artery Disease in Southern Iranian Population. *J Cardiovasc Thorac Res* 2014; 6(1): 51-5.
22. Pallant J. *SPSS Survival Manual: A step by step guide to data analysis using the SPSS program*. Crows Nest, Australia: Allen & Unwin; 2005. p. 249-50.
23. First MB, Spitzer RL, Gibbon M, Williams JB. *Structured clinical interview for DSM-IV AXIS I disorders SCID-I: clinician version, administration booklet*. Arlington, VA: American Psychiatric Press; 1997.
24. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the structured clinical interview for dsm-iv axis i disorders (SCID I) and axis ii disorders (SCID II). *Clin Psychol Psychother* 2011; 18(1): 75-9.
25. Sharifi V, Asadi SM, Mohammadi MR, Amini H, Kaviani H, Semnani Y, et al. Structured clinical interview for DSM-IV (SCID): Persian translation and cultural adaptation. *Iranian J Psychiatry* 2007; 2(1): 46-8. [In Persian].
26. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol* 1988; 56(6): 893-7.
27. Kaviani H, Mousavi AS. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). *Tehran Univ Med J* 2008; 66(2): 136-40. [In Persian].
28. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clinical Psychology Review* 1988; 8(1): 77-100.
29. Taheri Tanjani P, Garmaroudi Gh, Azadbakht M, Fekrizadeh Z, Hamidi R, Fathizadeh Sh, et al. Validity and reliability Beck Depression Inventory-II among the Iranian elderly Population. *J Sabzevar Univ Med Sci* 2015; 22(1): 189-98. [In Persian].
30. Hudson WW. Index of marital satisfaction. In: Corcoran K, Fischer J, Editors. *Measures for clinical practice and research, volume 1: couples, families, and children*. Oxford, UK: Oxford University Press; 2013.
31. Sanaei B. *Family and marriage scales*. Tehran, Iran: Beasat Publications; 2000. p. 45-9. [In Persian].
32. Moller-Leimkuhler AM. Women with coronary artery disease and depression: a neglected risk group. *World J Biol Psychiatry* 2008; 9(2): 92-101.
33. Suarez EC. Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. *Brain Behav Immun* 2008; 22(6): 960-8.
34. Watkins LL, Blumenthal JA, Babyak MA, Davidson JR, McCants CB Jr, O'Connor C, et al. Phobic anxiety and increased risk of mortality in coronary heart disease. *Psychosom Med* 2010; 72(7): 664-71.
35. Saeidi M, Komasi S, Soroush A, Zakiei A, Shakeri J. Gender differences in patients' beliefs about biological, environmental, behavioral, and psychological risk factors in a cardiac rehabilitation program. *J Cardio-Thoracic Med* 2014; 2(4): 215-20.
36. Perkins-Porras L, Whitehead DL, Steptoe A. Patients' beliefs about the causes of heart disease: relationships with risk factors, sex and socio-economic status. *Eur J Cardiovasc Prev Rehabil* 2006; 13(5): 724-30.
37. Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB Sr, Benjamin EJ. Marital status, marital strain, and risk of coronary heart disease or total mortality: the Framingham Offspring Study. *Psychosom Med* 2007; 69(6): 509-13.
38. Zare Z, Golmakani N, Shareh H, Shakeri MT, Khadem Ghaebi N. Factors related to marital satisfaction in primiparous women during postpartum period. *Journal of Midwifery and Reproductive Health* 2014; 2(2): 120-7. [In Persian].
39. Bannafatemeh H, Taheri Teymorlooei T. Social-culture factors determining the associated with marital satisfaction in married women in Azarshahr. *Sociology* 2009; 1(2): 7-29. [In Persian].

**How to cite this article:** Komasi S, Saeidi M. What is role of sex and age differences in marital conflict and stress of patients under Cardiac Rehabilitation Program? *ARYA Atheroscler* 2016; 12(3): 138-45.

# Predicting metabolic syndrome using decision tree and support vector machine methods

Farzaneh Karimi-Alavijeh<sup>(1)</sup>, Saeed Jalili<sup>(2)</sup>, Masoumeh Sadeghi<sup>(3)</sup>

## Original Article

### Abstract

**BACKGROUND:** Metabolic syndrome which underlies the increased prevalence of cardiovascular disease and Type 2 diabetes is considered as a group of metabolic abnormalities including central obesity, hypertriglyceridemia, glucose intolerance, hypertension, and dyslipidemia. Recently, artificial intelligence based health-care systems are highly regarded because of its success in diagnosis, prediction, and choice of treatment. This study employs machine learning technics for predict the metabolic syndrome.

**METHODS:** This study aims to employ decision tree and support vector machine (SVM) to predict the 7-year incidence of metabolic syndrome. This research is a practical one in which data from 2107 participants of Isfahan Cohort Study has been utilized. The subjects without metabolic syndrome according to the ATPIII criteria were selected. The features that have been used in this data set include: gender, age, weight, body mass index, waist circumference, waist-to-hip ratio, hip circumference, physical activity, smoking, hypertension, antihypertensive medication use, systolic blood pressure (BP), diastolic BP, fasting blood sugar, 2-hour blood glucose, triglycerides (TGs), total cholesterol, low-density lipoprotein, high density lipoprotein-cholesterol, mean corpuscular volume, and mean corpuscular hemoglobin. Metabolic syndrome was diagnosed based on ATPIII criteria and two methods of decision tree and SVM were selected to predict the metabolic syndrome. The criteria of sensitivity, specificity and accuracy were used for validation.

**RESULTS:** SVM and decision tree methods were examined according to the criteria of sensitivity, specificity and accuracy. Sensitivity, specificity and accuracy were 0.774 (0.758), 0.74 (0.72) and 0.757 (0.739) in SVM (decision tree) method.

**CONCLUSION:** The results show that SVM method sensitivity, specificity and accuracy is more efficient than decision tree. The results of decision tree method show that the TG is the most important feature in predicting metabolic syndrome. According to this study, in cases where only the final result of the decision is regarded significant, SVM method can be used with acceptable accuracy in decision making medical issues. This method has not been implemented in the previous research.

**Keywords:** Machine Learning, Metabolic Syndrome, Decision Tree, Support Vector Machine

*Date of submission:* 4 May 2014, *Date of acceptance:* 19 Apr 2016

### Introduction

Nowadays, the health-care systems based on the intelligent systems have been drawing a lot of attention. Medical decision support systems which can be used for predicting diseases, and assisting physicians in the diagnosis and treatment decisions,<sup>1,2</sup> and etc., can be mentioned

as a kind of intelligent system. A metabolic syndrome which has an upward trend due to industrialization of countries is one of the medical disorders. Lifestyle and dietary changes tending toward fast food, salty, and fatty food have increased metabolic syndrome in the communities.<sup>3</sup> Metabolic syndrome is a cluster

1- Department of Medical Informatics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2- Associate Professor, Department of Computer Engineering, School of Electrical and Computer Engineering, Tarbiat Modares University, Tehran, Iran

3- Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence to: Masoumeh Sadeghi, Email: sadeghimasoumeh@gmail.com

of conditions including high blood pressure (BP), abdominal obesity and hyperlipidemia and insulin resistance. In many cases, these conditions are present simultaneously.<sup>4</sup>

It is estimated that about 20-25% of the world's adult population suffer from the metabolic syndrome which doubles the risk of mortality in individuals. Moreover, risk of heart attack is 3 times as many and Type 2 diabetes is 5 times as many compared to people without the metabolic syndrome.<sup>4</sup>

In Asian countries, the metabolic syndrome has become an important issue due to changes in diet and lifestyle. In Iran, the prevalence of metabolic syndrome is spectacularly increasing that according to recent estimates equals generally 33 and 10-11% in normal weight adults.<sup>5,6</sup>

In recent years, artificial intelligence has been considered as a new approach of problem modeling. Nowadays, artificial intelligence has frequently been utilized to predict, diagnose and help medical diagnosis. Support vector machines (SVMs) and decision tree have been utilized for diagnosis and prediction of diseases in the medical domain. H. X. Liu et al. used the SVM to the diagnosis of breast cancer.<sup>7</sup> SVM was also applied to predicting central nervous system (CNS) permeability of drug molecules.<sup>8</sup> Decision tree algorithms have been used to prediction of pancreatic cancer<sup>9</sup> and identification of metabolic syndrome.<sup>10</sup> So far, this study has been accomplished to predict metabolic syndrome using SVM and decision tree. The purpose of this research is to predict the metabolic syndrome using decision tree and SVM decision methods.

In this study, decision tree and SVM methods are used to predict the metabolic syndrome since they are easy to understand and have a great efficiency, respectively.

## Materials and Methods

Data for this study included 2107 subjects participating in the research project of Isfahan Cohort Study (ICS).<sup>11</sup> The first phase of the research project of ICS began in January 2001 and lasted until October of 2001. In the first phase, 6323 people who have not been diagnosed

of heart disease were randomly selected. The second phase, in 2007, was re-conducted. In Phase II, the 3284 of them, after 7 years of follow-up, were re-evaluated. Among the participants in this project 2107 cases who did not suffer from metabolic syndrome in the first phase were chosen according to ATPIII. In the second phase of the study, 596 of them were diagnosed to suffer from metabolic syndrome. According to the criteria of ATPIII, there must exist at least three components of five following components<sup>12</sup> for the diagnosis of metabolic syndrome:

1. Hypertriglyceridemia  $\geq 150$  mg/dl
2. Low- and high-density lipoprotein cholesterol (HDL-C)  $< 40$  mg/dl in men and HDL  $< 50$  mg/dl in women
3. Fasting glucose  $\geq 100$  or use of diabetes medication
4. BP  $\geq 130/85$  mmHg or treatment with BP medication
5. Waist circumference (WC)  $\geq 95$  cm in men and women
6. WC is considered 95 cm for the Iranian people.<sup>13</sup>

The features that have been used in this data set include: Gender, age, weight, body mass index (BMI), WC, waist-to-hip ratio (WHR), hip circumference (HC), physical activity, smoking history, hypertension, antihypertensive medication use, systolic BP, diastolic BP, fasting blood glucose, 2-hour blood glucose, triglycerides (TGs), total cholesterol, low-density lipoprotein (LDL), HDL-C, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH).

The decision tree is a supervised machine learning technique. The results of this method can be presented in the form of a tree or a set of if-then rules.<sup>14</sup> The most significant feature in the decision tree method is the tree root. Other features are placed in the lower levels of tree in order of importance.<sup>15</sup> Finally, the leaves of the tree represent the classification result. This technique is widely used in various fields including the medical field. Many studies show that decision tree is an effective method in the analysis of medical data.<sup>9,10,15-17</sup> It has been applied in many studies because of its accurate and understandable results<sup>18</sup> which make the

decision tree more important than the other accurate methods.<sup>19</sup> After learning tree by starting from the root, and following the conditions in the intermediate nodes of the tree, we can easily follow the process of decision tree. Decision tree is one of the methods that have been employed to predict the metabolic syndrome; with this method, we can extract features that are effective in predicting the metabolic syndrome. Decision tree C4.5 tools use the entropy equation for determining the tree nodes. If  $S$  contains positive and negative examples of a target concept, the entropy of  $S$  will be defined by relation (1) relative to this Boolean classification.  $P_{\oplus}$  is the ratio of positive examples to all examples and  $P_{\ominus}$  is the ratio of negative examples to all examples.


$$\text{Entropy}(S) = -P_{\oplus}\log_2(P_{\oplus}) - P_{\ominus}\log_2(P_{\ominus}) \quad (1)$$

### SVM

Another machine learning methods are SVM that can be used for classification and regression and recently has been widely used in the medical domain. Among them, studies in the following fields can be cited: diagnosis of heart diseases,<sup>20</sup> predicting diabetes<sup>21</sup> and diagnosis of breast cancer.<sup>7,22</sup> Unlike the decision tree method, SVM is more a liked a black box, in other words, the knowledge derived from SVM is not directly sensible by professionals. However, SVM accuracy in classification has been caused its variety of applications. In this approach, each data is a vector where its dimensions is equal to the number of features to be considered and SVM creates a hyperplane that separates samples of two categories. Such of the induced, created hyperplane has a maximum distance between the margin samples of between two classes. Figure 1 represents the solution for a two features problem.

Remember that SVM kernel maps the data that are linearly inseparable to a non-linear feature space and then induces a hyperplane between two classes.<sup>23</sup> The advantage of this method is its implementation simplicity and, unlike the neural network does not get stuck in a local maximum.<sup>8</sup> However, the only thing that should be carefully regarded is selecting the kernel type in this method.<sup>7</sup> Type of selected kernel has a considerable impact on the

prediction accuracy. The most commonly used kernels in SVM are the radial basis function (RBF), polynomial, sigmoid and linear. The  $C$  parameter must be set in all of them jointly. This parameter has an effect on the decision boundaries. As the value of  $C$  is increased, the distance between the boundaries of two classes is reduced. By changing  $C$ , a balance is established between the error and accuracy of the included hyperplane. Each kernel has its own parameters for setting which determines the degree of flexibility between the two classes. This study uses SVM method with polynomial kernel.



**Figure 1.** The induced line for the separation of positive and negative samples

Balance in data set is another subject that impacts the performance of machine learning methods. In the real world, especially in the medical field, the number of positive samples is much less than the negative samples.<sup>24,25</sup> On the other hand, in this field, accurate prediction and diagnosis of positive samples is very important. In medical issues, a high sensitivity is more important than high specificity. The lack of positive data causes the learned model is based on negative data which means they learn the classes containing negative data and ignore the minority positive samples. For example, in a dataset, if the number of positive samples would be 1%, the specificity and accuracy will be 100 and 99%, respectively, while it is the negative class that is learned. Instead of the positive class,<sup>25</sup> one-way to fix this problem is to balance the given data set can be used. In this research,

due to the unbalanced given data set Synthetic Minority Over-sampling Technique (SMOTE) method is used to balance the given data set. In this method, with the help of minima samples, a new synthetic data set is generated using the nearest neighbor.<sup>24</sup>

In general, there are several criteria to evaluate the success rate of a learning model. In this study, the criteria of sensitivity, specificity and accuracy are used. Furthermore, in this study, we have used 10-fold cross validation for performance evaluation of prediction metabolic syndrome.<sup>26</sup>

These criteria are calculated according to the values of the confusion matrix. The confusion matrix displays the results of predicting the classify problem samples compared to their original classes. In a problem with two classes including patient and healthy, there is a  $2 \times 2$  confusion matrix. Four members of this matrix are numbers that show the true positive (TP), false positive (FP), true negative (TN), and false negative (FN). Criteria of sensitivity, specificity and accuracy are calculated using elements of the confusion matrix. Sensitivity as is shown in relation<sup>3</sup> is an accuracy rate of the right diagnosis in patients with metabolic syndrome. Specificity as is shown in relation<sup>4</sup> is the accuracy rate of right diagnosis of normal subjects. Accuracy as is shown in relation<sup>5</sup> is the rate of the right diagnosis of metabolic syndrome and healthy subjects.

$$\text{Sensitivity} = \frac{TP}{TP + FN} \quad (2)$$

$$\text{Specificity} = \frac{TN}{FP + TN} \quad (3)$$

$$\text{Accuracy} = \frac{TP + TN}{TP + TN + FN + FP} \quad (4)$$

We use 10-fold cross validation approach to validate the performance of predictive models.<sup>14</sup>

The experiments of research are conducted using the WEKA open source software (Waikato

Environment for Knowledge Analysis, University of Waikato, New Zealand).

## Results

We used ICS data set to determine the input factors (gender, age, weight, BMI, WC, WHR, HC, physical activity, smoking history, hypertension, antihypertensive medication use, systolic BP, diastolic BP, fasting blood glucose, 2-hour blood glucose, TGs, total cholesterol, LDL, HDL-C, MCV and MCH) (Table 1). Details of ICS study were reported previously.<sup>27</sup>

**Table 1.** Baseline subject characteristics in this study

Characteristics	Total (n = 2107) Mean (Min-Max)
Age	48.07 (34.0-86.0)
Weight	67.97 (39.0-120.0)
BMI	25.67 (14.96-39.9)
HC	99.77 (53.0-143.0)
WC	90.96 (52.0-131.0)
WHR	91.16 (0.7-1.2)
SBP	115.52 (75.0-200.0)
DBP	75.27 (20.0-150.0)
FBS	79.66 (41.0-298.0)
2-HP	97.22 (60.0-383.0)
HDL	48.48 (25.0-79.0)
LDL	125.70 (15.0-316.0)
TG	164.11 (47.0-726.0)
TCH	206.68 (76.0-450.0)
MCV	86.63 (44.0-106.0)
MCH	28.45 (0.0-42.3)

BMI: Body mass index; HC: Hip circumference; WC: Waist circumference; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FBS: Fasting blood sugar; HDL: High density lipoprotein; LDL: Low-density lipoprotein; TG: Triglycerides; TCH: Total cholesterol; MCV: Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; 2-HP: 2-hour postprandial blood sugar

The results of the experimenting of the decision tree algorithm and SVM on ISC data set is presented in table 2. According to table 2, the sensitivity of the decision tree and SVM are 0.337 and 0.320, respectively. These sensitivity values are very low for predicting, so the result is not acceptable.

**Table 2.** The sensitivity, specificity and accuracy of the learning methods applied on the unbalanced Isfahan Cohort Study (ICS) data set

Method	Sensitivity	Specificity	Accuracy
Decision tree	0.337	0.917	0.75273
SVM	0.320	0.934	0.76032

SVM: Support vector machine


**Table 3.** The sensitivity, specificity and accuracy of the learning methods applied on the balanced Isfahan Cohort Study (ICS) data set

Method	Sensitivity	Specificity	Accuracy
Decision tree	0.758	0.72	0.739
SVM	0.774	0.74	0.757

SVM: Support vector machine

The lack of sensitivity is due to the ICS unbalanced data set. Following the lack of positive samples compared to with the negative samples, the model learns healthy subjects instead of patient subjects. To vanish this problem we used, SMOTE method to balance ICS data set. We applied decision tree and SVM method on the balanced ICS data set. The results are presented in table 3.


The value of the parameter C [ $2^{(-5)}$ ,  $2^{(-3)}$ , ...,  $2^{10}$ ] with polynomial degree 2, 3 and 4 are used in SVM method. To determine the optimal value C, values between two consecutive C are tested again, after obtaining the highest value of C. Finally, the highest accuracy is obtained at C = 24. This accuracy is obtained with polynomial kernel of degree 4. Changes in accuracy, sensitivity and specificity based on C, is presented in figure 2.



**Figure 2.** The sensitivity, specificity and accuracy of support vector machine, based on C in polynomial kernel of degree 4 applied on the balanced Isfahan cohort study data set

The decision tree method is studied for the confidence factor between 0.01 and 0.99. The best accuracy is obtained with a confidence factor equal to 0.06. Figure 3 shows the effectiveness of in sensitivity, specificity and accuracy of decision tree C4.5 with respect to

changes of the confidence factor.




**Figure 3.** The sensitivity, specificity and accuracy of the decision tree C4.5 with different on faience factor applied on the balanced Isfahan Cohort Study data set

In this study, we have used four methods for performance evaluation of prediction metabolic syndrome. These methods are classification accuracy, analysis of sensitivity and specificity, and 10-fold cross validation.

Comparison of the decision tree and SVM methods based on figure 4 shows that SVM has better accuracy and efficiency than the decision tree. However, the advantages of decision tree in comparison with SVM are a high speed and low-cost learning and prediction. The decision tree generated in this study shows that TG is the main prognostic factor of metabolic syndrome. A combination of TGs + BMI is an accurate predictor for predicting. Moreover, according to the induced decision tree, a person with TGs > 223 and BMI ≥ 24.35, with probability 85%, will suffer the metabolic syndrome.

### Discussion

The purpose of this study is comparing the prediction of metabolic syndrome using decision tree and SVM methods. The decision tree method is chosen because the induced tree is understandable and shows the process of prediction.



**Figure 4.** The sensitivity, specificity and accuracy of the learning methods applied on the balanced Isfahan cohort study data set

SVM: Support vector machine

According to studies, the method of SVM also has a high accuracy. The most significant feature in the decision tree method is the tree root. In the constructed decision tree, TGs represent the root. Therefore, TGs is the most important feature for classifying the metabolic syndrome. The derived results are corresponded with research by Worachartcheewan et al.<sup>10</sup> as “identification of metabolic syndrome using decision tree analysis.” According to this study, participants had BMI  $\geq 25$ . The results of this study show that TGs is an important feature for the diagnosis of metabolic syndrome and combining (TG + BP) and (TG + BP + glucose) are as an accurate predictor of metabolic syndrome. In another study by Lemieux et al.,<sup>28</sup> it is found that TGs is the most important feature for predicting the metabolic syndrome.

However, it is noted in other studies, using SVM is one of the most successful methods of classification. In our study, SVM method shows that it is more efficient than a decision tree method based on the criteria of sensitivity, specificity and accuracy. Note that, previously, SVM method is not used to predict metabolic syndrome.

### Conclusion

One of the main objectives in the field of health is diseases prevention. One of the most effective actions to prevent diseases is prediction of disease in susceptible individuals. One of the effective methods for prediction of diseases is the use of methods of statistical inference and

artificial intelligence. Statistical methods do not provide acceptable results in nonlinear and complex problems where features are dependent.<sup>3</sup> In recent years, machine learning techniques are frequently used in medical issues, and they acceptable results in predicting and diagnosing of diseases. Since to the metabolic syndrome is a precursor to heart disease and diabetes and increases the risk of these diseases so Predicting and analyzing the characteristics of this disorder, it can be an effective step in preventing these diseases. According to the results obtained in our study, increasing of TGs, BP, and BMI are regarded as the most important causes of this disorder. These factors are easily modifiable by changes in the lifestyle and the use of healthy eating.

Furthermore, due to the high efficiency of SVM method, this method can be used for prediction and generality issues related to the classification in the medical domain. According to the results of the two learning candidate methods, in order to have a more accurate prediction for new instances of the disorder we recommend to use SVM method. Prediction of ATPIII based metabolic syndrome using machine learning.

### Acknowledgments

This article is the result of a master's thesis on the topic of “Prediction of ATPIII based metabolic syndrome using machine learning” in 2014. The authors are grateful to the Cardiovascular Research Center, Isfahan University of Medical Sciences for providing the ICS data set, Dr. Mohammad Talaei, Head cohort unit, for collaboration.

### Conflict of Interests

Authors have no conflict of interests.

### References

1. Karabatak M, Ince MC. An expert system for detection of breast cancer based on association rules and neural network. *Expert Syst Appl* 2009; 36(2, Part 2): 3465-9.
2. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. *Nat Med* 2001; 7(6): 673-9.
3. Hirose H, Takayama T, Hozawa S, Hibi T, Saito I.

- Prediction of metabolic syndrome using artificial neural network system based on clinical data including insulin resistance index and serum adiponectin. *Comput Biol Med* 2011; 41(11): 1051-6.
4. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [Online]. [cited 2006]; Available from: URL: [http://www.idf.org/webdata/docs/MetS\\_def\\_update\\_2006.pdf](http://www.idf.org/webdata/docs/MetS_def_update_2006.pdf)
  5. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATP III and the WHO definitions. *Diabetes Res Clin Pract* 2007; 77(2): 251-7.
  6. Esteghamati A, Ashraf H, Rashidi A, Meysamie A. Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults. *Diabetes Res Clin Pract* 2008; 82(1): 104-7.
  7. Liu HX, Zhang RS, Luan F, Yao XJ, Liu MC, Hu ZD, et al. Diagnosing breast cancer based on support vector machines. *J Chem Inf Comput Sci* 2003; 43(3): 900-7.
  8. Doniger S, Hofmann T, Yeh J. Predicting CNS permeability of drug molecules: comparison of neural network and support vector machine algorithms. *J Comput Biol* 2002; 9(6): 849-64.
  9. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. *Oncology* 2005; 68(1): 79-86.
  10. Worachartcheewan A, Nantasenamat C, Isarankura-Na-Ayudhya C, Pidetcha P, Prachayasittikul V. Identification of metabolic syndrome using decision tree analysis. *Diabetes Res Clin Pract* 2010; 90(1): e15-e18.
  11. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. *Arch Iran Med* 2013; 16(3): 138-44.
  12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005; 112(17): 2735-52.
  13. Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. *Arch Iran Med* 2010; 13(3): 243-4.
  14. Witten LH, Frank E. *Data mining: practical machine learning tools and techniques*. Burlington, MA: Morgan Kaufmann; 2005.
  15. Jerez-Aragones JM, Gomez-Ruiz JA, Ramos-Jimenez G, Munoz-Perez J, Alba-Conejo E. A combined neural network and decision trees model for prognosis of breast cancer relapse. *Artif Intell Med* 2003; 27(1): 45-63.
  16. Palaniappan S, Awang R. Intelligent heart disease prediction system using data mining techniques. *Proceedings of the IEEE/ACS International Conference on Computer Systems and Applications*; 2008 Mar 31-Apr 4; Doha, Qatar.
  17. Anbananthen KS, Sainarayanan G, Chekima A, Teo J. Artificial neural network tree approach in data mining. *Malaysian Journal of Computer Science* 2007; 20(1): 51-62.
  18. Murthy SK. *Automatic Construction of Decision Trees from Data: A Multi-Disciplinary Survey*. *Data Min Knowl Discov* 1998; 2(4): 345-89.
  19. Alpaydin E. *Introduction to machine learning*. 2<sup>nd</sup> ed. Cambridge, MA: MIT Press; 2010.
  20. Yan WW, Shao HH. Application of support vector machines and least squares support vector machines to heart disease diagnoses. *Control and Decision* 2003; 18(3): 358-60.
  21. Yu W, Liu T, Valdez R, Gwinn M, Khoury MJ. Application of support vector machine modeling for prediction of common diseases: the case of diabetes and pre-diabetes. *BMC Med Inform Decis Mak* 2010; 10: 16.
  22. Akay MF. Support vector machines combined with feature selection for breast cancer diagnosis. *Expert Syst Appl* 2009; 36(2): 3240-7.
  23. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. *Bioinformatics* 2000; 16(10): 906-14.
  24. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic minority over-sampling technique. *J Artif Intell Res* 2002; 16: 321-57.
  25. Zhang D, Liu W, Gong X, Jin H. A Novel Improved SMOTE Resampling Algorithm Based on Fractal. *Journal of Computational Information Systems* 2011; 7(6): 2204-11.
  26. Alpaydin E. *Introduction to machine learning*. 3<sup>rd</sup> ed. Cambridge, MA: MIT Press; 2014.
  27. Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, et al. The Isfahan cohort study: rationale, methods and main findings. *J Hum Hypertens* 2011; 25(9): 545-53.
  28. Lemieux I, Poirier P, Bergeron J, Almeras N, Lamarche B, Cantin B, et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? *Can J Cardiol* 2007; 23(Suppl B): 23B-31B.

**How to cite this article:** Karimi-Alavijeh F, Jalili S, Sadeghi M. **Predicting metabolic syndrome using decision tree and support vector machine methods.** *ARYA Atheroscler* 2016; 12(3): 146-52.

## Reversible left bundle branch block should be mentioned in cardiac resynchronization therapy; A clinical case report

Ali Vasheghani-Farahani<sup>(1)</sup>, Masih Tajdini<sup>(2)</sup>, Seyed Abolfazl Mohsenizadeh<sup>(2)</sup>, Seyed Mohammad Reza Hosseini<sup>(3)</sup>

### Case Report

#### Abstract

**BACKGROUND:** Cardiac resynchronization therapy (CRT) is a medical device to help cardiac synchronized contractility by electrical impulses. Improvement of symptoms and left ventricular systolic function, reducing hospital admissions and mortality in patients with moderate to severe heart failure are the main benefits of administration of cardiac resynchronization therapy.

**CASE REPORT:** In this article, we describe a case of heart failure and left bundle branch block (LBBB) who was candidate for cardiac resynchronization therapy; but after managing hyperkalemia, left bundle branch block resolved, ejection fraction increased and cardiac resynchronization therapy implantation was canceled.

**CONCLUSION:** Exclusion of treatable causes is the first important step before any interventions. Now there is an important question; is cardiac resynchronization therapy effective in patients with heart failure and transient or intermittent left bundle branch block?

**Keywords:** Reversible Left Bundle Branch Block, Cardiac Resynchronization Therapy, Hyperkalemia

*Date of submission:* 2 Mar 2015, *Date of acceptance:* 15 Apr 2016

#### Introduction

Wide QRS, mainly left bundle branch block (LBBB) is an independent predictor of adverse prognosis in patients with heart failure. Cardiac resynchronization therapy (CRT) is a medical device to help cardiac synchronized contractility by electrical impulses.<sup>1</sup>

CRT is indicated for patients who have left ventricular ejection fraction of less than 35 percent, LBBB with QRS duration of  $\geq 120$  ms (especially when is more than 150 ms) and New York Heart Association (NYHA) of class II, III, or ambulatory IV symptoms while receiving guideline-directed medical therapy (GDMT).<sup>2</sup>

#### Case Report

A 71-year-old woman referred to our clinic with dyspnea on exertion (DOE). Her dyspnea was progressed from class II to IV during the last month (based on NYHA classification). Past medical history was positive for hypertension

and hypothyroidism. She was under heart failure regimen drugs [angiotensin II receptor blocker (ARB), aldosterone antagonist, digoxin, diuretic and beta blocker], and prednisolone for her thyroid-related ophthalmopathy condition.

On physical examination, holosystolic murmur in left sternal border (LSB) and coarse crackle on both lungs was heard. About + to ++ non-pitting edema was observed in lower limbs. Electrocardiogram (ECG) was in favor of normal sinus rhythm, left axis deviation, LBBB pattern with QRS duration of approximately 160 ms and wide base tall T waves in precordial leads (Figure 1).

Echocardiographic evaluations including tissue doppler imaging (TDI) and tissue synchronization imaging (TSI) were suggested significant intraventricular and interventricular dyssynchrony and ejection fraction of about 30 percent.

Due to these findings and based on 2012 American College of Cardiology Foundation/American Heart Association/Heart

1- Associate Professor, Tehran Heart Center AND Department of Cardiology, Tehran University of Medical Sciences, Tehran, Iran

2- Resident, Tehran Heart Center AND Department of Cardiology, Tehran University of Medical Sciences, Tehran, Iran

3- General Practitioner, Department of Radiology, Massachusetts General Hospital, Boston, MI


Correspondence to: Masih Tajdini, Email: drmasih84@yahoo.com

Rhythm Society (ACCF/AHA/HRS) Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities, the patient was candidate for CRT.


Routine laboratory tests such as electrolytes level, creatinine, complete blood count, coagulation tests, thyroid function tests and digoxin level were requested. All of aforementioned lab results were in normal ranges except potassium ( $k = 7.49$  mEq/l), hemoglobin [10.3 g/l with mean corpuscular

volume (MCV) of 85 fl] and creatinine (Cr = 1.52 mg/dl).

Therefore, acute treatment strategies were started for hyperkalemia. After treatment, the level of potassium was dropped to 4.3 mEq/l. Surprisingly, ECG converted to normal sinus rhythm with normal QRS duration and no ST-T changes (Figure 2). Echocardiography was done again and revealed an ejection fraction of about 40 percent.



**Figure 1.** With this the patient was candidate for cardiac resynchronization therapy (CRT)



**Figure 2.** After potassium level correction

## Discussion

Improvement of symptoms and left ventricular systolic function, reducing hospital admissions and mortality in patients with moderate to severe heart failure are the main benefits of CRT administration.<sup>3</sup>

Potassium level of more than 5.5 mEq/l is defined as hyperkalemia. Hyperkalemia has different causes but most often, it is due to renal impairment of potassium excretion, potassium sparing drugs (such as renin-angiotensin inhibitors and aldosterone antagonist diuretics) and cellular release of potassium. Hyperkalemia has different effects on ECG including narrow and tall T wave, shortening of QT interval, QRS widening, prolonged PR interval and loss of P wave.<sup>4</sup>

Based on our literature search, except hyperkalemia there are some causes of transient LBBB; a) Thyrotoxicosis, in a case report, LBBB in a young woman resolved by thyrotoxicosis treatment;<sup>5</sup> b) Rate-dependent bundle branch block that may happen with tachycardia in the setting of heart failure decompensation;<sup>6</sup> c) Acute carbon monoxide poisoning;<sup>7</sup> d) Vasospasm;<sup>8</sup> and e) Left coronary fistula.<sup>9</sup>

Our patient had transient LBBB due to hyperkalemia. We recognized chronic hyperkalemia as the main etiology of wide QRS in our patient. The ECG turned back to normal after K level was corrected. CRT was not a treatment of choice for this patient as result of acceptable ejection fraction and narrow QRS. So, exclusion of treatable causes is the first important step before any interventions. Now there is an important question; is CRT effective in patients with heart failure and transient or intermittent left bundle branch block?

## Acknowledgments

We would like to express our special thanks to the staff of Department of Cardiology, Tehran Heart Center, Tehran, Iran.

## Conflict of Interests

Authors have no conflict of interests.

## References

1. Willis HJ. Left bundle-branch block-pathophysiology, prognosis, and clinical management. *Clin Cardiol* 2007; 30(10): 535.
2. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA 3<sup>rd</sup>, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2012; 60(14): 1297-313.
3. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. *Circulation* 2003; 107(15): 1985-90.
4. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. *J Emerg Med* 2004; 27(2): 153-60.
5. Wilmot E, Sagili V, Sturrock N. An rare cause of reversible left bundle branch block. *Endocrine Abstracts* 2007; 13: 23.
6. Fisher JD, Aronson RS. Rate-dependent bundle branch block: occurrence, causes and clinical correlations. *J Am Coll Cardiol* 1990; 16(1): 240-3.
7. Parenti N, Binetti N, Lenzi T. "Reversible" left bundle branch block in acute carbon monoxide poisoning. *Intern Emerg Med* 2006; 1(2): 172-3.
8. Alhaji M. Intermittent left bundle branch block caused by coronary vasospasm. *Avicenna J Med* 2013; 3(2): 50-2.
9. Juraschek SP, Kovell LC, Childers RE, Chow GV, Hirsch GA. Heart failure with transient left bundle branch block in the setting of left coronary fistula. *Cardiol Res Pract* 2011; 2011: 786287.

**How to cite this article:** Vasheghani-Farahani A, Tajdini M, Mohsenizadeh SA, Hosseini SMR. **Reversible left bundle branch block should be mentioned in cardiac resynchronization therapy; A clinical case report.** *ARYA Atheroscler* 2016; 12(3): 153-5.

## Normal range of bleeding time in west of Iran

Hassan Mansouritorghabeh<sup>(1)</sup>

### Letter to Editor

Date of submission: 31 Aug 2014, Date of acceptance: 22 Aug 2015

#### Introduction

I read with great interest the contribution of Maleki et al. entitled "Normal range of bleeding time in urban and rural areas of Borujerd, west of Iran" that has been published in recent issue of ARYA Atherosclerosis.<sup>1</sup>

The bleeding time test (BTT) is an old in-vivo test for evaluation of platelets function and vascular integrity with low producibility.<sup>2</sup> Its procedure and performance is simple and due to its high dependence on operator skills, every laboratory should determine its reference range by itself and by one operator.<sup>3</sup> So, if you determine a reference range by a laboratory (an operator) it may not cover the same population tested by another laboratory (another operator) exactly.

The authors declared that participants were selected among patients referred to 9 rural and 16 urban medical centers. In an epidemiological study, to determine the reference range for a biologic parameter, it would be more logic and accurate to select participants among normal general population randomly to avoid any bias in results. The sampling methods in this regards have been fully addressed in biostatistics field.<sup>4</sup>

Besides, it is reported that all measurements of BTT were done by samplers in each medical center; as there were 25 medical centers for carrying out BTT, an important issue is how the authors are sure about standard incisions made by hand by various technicians while investigators did not use standard instrument for incision such as Template or Simplate.<sup>5</sup> As mentioned earlier, the results of BTT are highly dependent on operator's skill due to improperly performed puncture and can affect the results.

The difference of current reference range of

BT in Borujerd that is different from worldwide reference range comprises that an important finding needs to be interpreted and addressed as this study has focused on reference range of BT in the region.

Owing to the authors cited "BT of the samples was determined according to Ivy simplate method considering national standard protocol in the selected persons" it would be cleared that according to Ivy protocol the BT is done directly on participants' forearms and there is no sample to be used in the procedure. In addition, there are four known different procedures that are in use for BTT; 1) The Duke method, 2) The Ivy method, 3) The Mielke method and 4) The simplate or surgicutt method. The former method is modified version of Ivy method and is done by a standard and sterile device (Figure 1) that makes a uniform incision. As the authors declared they have used a lancet for making an incision, naming Ivy simplate in the text is confusing.




Figure 1. A schematic sample of incision devices are used in Ivy simplate or surgicutt method

#### Conflict of Interests

Authors have no conflict of interests.

#### References

1. Maleki A, Rashidi N, Almasi V, Montazeri M, Foroughi S, Alyari F. Normal range of bleeding time in urban and rural areas of Borujerd, west of Iran.

1- Allergy Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran  
Correspondence to: Hassan Mansouritorghabeh, Email: mansouritorghabeh@mums.ac.ir

- ARYA Atheroscler 2014; 10(4): 199-202.
2. Hankey GJ, Eikelboom JW. Aspirin resistance. *Lancet* 2006; 367(9510): 606-17.
  3. Laffan MA, Manning RA. Investigation of haemostasis. In: Lewis SM, Bain BJ, Bates I, Editors. *Dacie and lewis practical haematology*. 9<sup>th</sup> ed. London, UK: Churchill Livingstone; 2001. p. 371-3.
  4. Dillman DA, Eltinge JL, Groves RM, Little RJ. Survey nonresponse in design, data collection, and analysis. In: Groves RM, Editor. *Survey nonresponse*. New York, NY: Wiley; 2002. p. 3-26.
  5. Kumar R, Ansell JE, Canoso RT, Deykin D. Clinical trial of a new bleeding-time device. *Am J Clin Pathol* 1978; 70(4): 642-5.

**How to cite this article:** Mansouritorghabeh H. **Normal range of bleeding time in west of Iran.** *ARYA Atheroscler* 2016; 12(3): 156-7.

